The impact of rare diseases on the quality of life in paediatric patients: current status

Rare diseases, also known as orphan diseases, are a group of disorders that affect a small percentage of the population. Despite individually affecting a small number of people, collectively, they impact millions worldwide. This is particularly significant in paediatric patients, highlighting the global scale of the issue. This review delves into the exact prevalence of rare diseases among children and adolescents and their diverse impact on the quality of life of patients and their families. The review sheds light on the complex interplay of genetic and environmental factors contributing to these conditions and the diagnostic challenges and delays often encountered in identifying and categorising these diseases. It is noted that although there have been significant strides in the field of genomic medicine and the development of orphan drugs, effective treatments remain limited. This necessitates a comprehensive, multidisciplinary approach to management involving various specialities working closely together to provide holistic care. Furthermore, the review addresses the psychosocial and economic burdens faced by families with paediatric patients suffering from rare diseases, highlighting the urgent need for enhanced support mechanisms. Recent technological and therapeutic advancements, including genomic sequencing and personalized medicine, offer promising avenues for improving patient outcomes. Additionally, the review underscores the role of policy and advocacy in advancing research, ensuring healthcare access, and supporting affected families. It emphasises the importance of increased awareness, education, and collaboration among healthcare providers, researchers, policymakers, and patient advocacy groups. It stresses the pivotal role each group plays in improving the diagnosis, treatment, and overall quality of life for paediatric patients with rare diseases.

1 Introduction

Rare diseases (RDs) are considered chronic, progressive, and life-threatening conditions that impact a small percentage of the population, resulting in elevated levels of pain and suffering. These diseases lack effective treatments, and the symptoms exhibit considerable variability among individuals (1, 2). The absence of a universal definition poses a critical constraint in determining the prevalence of rare diseases (3). The lack of a universally accepted definition for rare diseases is the result of both practical challenges and regional economic factors. For instance, the United States applies an absolute number criterion based on the potential profitability of developing orphan drugs, whereas the European Union utilises a relative number criterion that considers its diverse population sizes (4). However, this criterion may not be applicable in areas with varying population sizes or where there are only a limited number of diagnosed rare disease patients. In Latin America, for example, there is no consensus on what constitutes a rare disease (5). Consequently, these differing approaches complicate global efforts to standardize the definition of rare diseases.

Following the adoption of the UN resolution on rare diseases, Rare Diseases International (RDI), a global network representing individuals affected by rare diseases, has played an instrumental role in advocating for a standardized definition of these conditions. Thus, in 2015, RDI proposed a universal definition of rare diseases, aiming to create a more cohesive approach to addressing these conditions across borders. However, despite RDI’s recommendations and the implementation of various global frameworks, each country continues to establish its own criteria for defining rare diseases, primarily based on factors such as disease prevalence, the impact on the population, and the capacity of healthcare systems to provide adequate treatment (6). This lack of uniform adoption has led to challenges in ensuring equitable access to healthcare and treatments for rare disease patients worldwide.

The absence of epidemiological data compounds this challenge, impeding a comprehensive understanding of their incidence and impact on individuals and society. Children with rare diseases face a more complex and uncertain future than children with more common diseases. An estimated 10,000 distinct rare diseases have been identified, with over half afflicting children and contributing to approximately 75% of all cases, primarily driven by genetic mutations accounting for about 80% of cases (7).

Globally, approximately 400 million individuals are impacted by rare diseases, and half of these are children (8, 9). The burden of these diseases encompasses significant implications for patients, their families, and the healthcare system. Furthermore, the absence of efficacious treatments exacerbates the burden, leading to heightened morbidity and mortality. A comprehensive understanding of rare disease burden is imperative for developing effective public health policies and targeted interventions.

2 Prevalence

The assessment of rare disease prevalence poses challenges due to significant variability across geographic regions. Recent data indicates that approximately 400–475 million individuals are affected by rare diseases, with an estimated 370–500 million being Indigenous people who encounter difficulties in accessing rare disease diagnosis, treatment, and healthcare services (10). A recent study shows an increase in rare disease prevalence from 10.57 to 33.21 cases per 100,000 individuals, reflecting an average annual rise of 19.46% (11). Nearly 75% of rare disease cases manifest in children, and regrettably, 30% of affected children do not survive beyond the age of five. Furthermore, 80% of rare diseases have been attributed to genetic factors (12, 13). To underscore the impact of these statistics, it is notable that half of all rare disease patients are children, three out of ten afflicted children do not reach their fifth birthday, and genetic mutations account for eight out of ten rare diseases (8, 9). The rise in the prevalence of rare diseases is not because the situation is deteriorating but due to advancements in diagnostic techniques, improved access to healthcare, and heightened awareness of these conditions. For instance, in Taiwan, advancements in diagnostic capabilities have led to an increased identification of rare diseases that were previously underdiagnosed (11). This rising prevalence should not be interpreted as a sign of worsening public health; instead, it represents a positive outcome resulting from enhancements in healthcare systems.

Regionally, a significant portion of the EU population, ranging from 27 to 36 million individuals, is impacted by approximately 8,000 rare diseases, with 50–75% of these cases affecting children (14, 15). In the United States, rare diseases are estimated to affect around 25–30 million people, encompassing one in ten Americans (8, 16). Australia is home to an estimated two million individuals affected by rare diseases, including 400,000 children (17, 18). The exact prevalence of rare diseases in China is undetermined, with some affecting fewer than 140,000 individuals and others impacting up to 49–82 million people (19, 20). Estimates suggest that around 50 million Africans, 40–50 million individuals in Latin America, and 25 million people in the Middle East are affected by rare diseases (21).

A recent systematic review has emphasized the varying prevalence of rare diseases based on disease type - metabolic disorders being the most common subgroup, affecting an estimated 1 in 1,458 individuals, while immunological and haematological disorders are reported as the rarest, with an impact of 1 in 6,000 individuals (22, 23). The lack of comprehensive data on rare diseases presents challenges in understanding their precise prevalence and societal impact, especially in paediatric patients.

3 Genetic and environmental factors

Most rare diseases are genetic, resulting from mutations in one or more genes. These genetic mutations can be inherited from parents or occur de novo. For example, cystic fibrosis is caused by mutations in the CFTR gene, which can be exacerbated by environmental factors like lung infections, which can worsen the disease (24). In contrast, Duchenne muscular dystrophy is caused by mutations in the DMD gene (25). Some rare diseases result from chromosomal abnormalities, such as deletions, duplications, or translocations. An example is Williams syndrome, caused by a deletion of genetic material on chromosome 7 (26). Many rare diseases are inherited in an autosomal recessive, autosomal dominant, or X-linked manner. For instance, Tay-Sachs disease is inherited in an autosomal recessive pattern (27). Rett syndrome is typically caused by de novo mutations in the MECP2 gene on the X chromosome (28). Some rare diseases result from new (de novo) mutations that occur spontaneously during the formation of reproductive cells or in early embryonic development. Progeria (Hutchinson-Gilford progeria syndrome) often results from a de novo mutation in the LMNA gene (29). Environmental factors can also play a role in the expression and progression of these diseases, although this is less common. Exposure to certain environmental factors during pregnancy can increase the risk of rare diseases. For instance, maternal infections, substance abuse, or exposure to toxins can result in congenital anomalies (30, 31). Exposure to environmental toxins, such as heavy metals or pesticides, can increase the risk of developing rare diseases. This exposure can occur prenatally or during early childhood. Environmental factors can cause epigenetic changes that influence gene expression without altering the DNA sequence (32, 33). These changes can contribute to the development of rare diseases or affect their progression. In some cases, a combination of genetic predisposition and environmental triggers can lead to the onset of a rare disease. Many rare diseases result from a complex interplay between genetic predispositions and environmental influences. For example, in individuals with a genetic susceptibility to a disease, environmental factors such as diet, lifestyle, and exposures can influence the severity and onset of the condition (34, 35).

Understanding both genetic and environmental factors is crucial for diagnosing, managing, and potentially preventing rare diseases in children. This comprehensive approach helps develop targeted therapies and improve the quality of life for affected individuals.

4 Diagnosis

Patients with rare diseases encounter substantial challenges stemming from diagnostic delays. These delays are frequently attributed to initial misdiagnosis, insufficient awareness among healthcare professionals, and restricted access to specialized diagnostic facilities. Prolonged diagnostic timelines can exacerbate the severity of consequences, such as disease progression, irreversible organ damage, and diminished treatment efficacy, underscoring the imperative for heightened medical professional awareness (36, 37). Recent studies have revealed that the average diagnostic journey for rare disease patients exceeds five years (38, 39). Furthermore, another study reported a median duration of 75 months (40). Diagnostic delays and misdiagnosis can be attributed to various factors, including the rare nature of these diseases, which pose challenges in data aggregation, in addition to data heterogeneity and fragmentation with inadequate interoperability, compounded by the absence of a comprehensive repository for rare diseases (41).

A previous study identified inaccessibility and lack of referral as the primary reasons for diagnostic delays, followed by service unavailability and protracted waiting times for affected patients (42). Consequently, the medical journey for rare disease patients entails multiple referrals and extensive testing, occasionally yielding inconclusive diagnoses (37, 43). While common diseases are typically prioritized in the diagnostic process, the low prevalence of rare diseases often results in their being overlooked. Consequently, patients affected by rare diseases must navigate the complexities of their conditions amidst a lack of specialized expertise and knowledge. Furthermore, the absence of targeted health policies contributes to diagnostic delays and restricted access to healthcare services. This combination can lead to significant physical, psychological, and cognitive impairments, and, in certain instances, may result in inadequate or even harmful treatments (36).

The utilization of genomic sequencing has seen a significant rise in the diagnosis of a wide array of diseases, including rare ones (40, 44). In recent years, there has been a paradigm shift in diagnosing rare diseases of epigenetic origin (RDEOs) owing to the transformative impact of next-generation sequencing techniques. High-throughput sequencing has proven effective in detecting and uncovering genetic variants, particularly in rare genetic diseases (8, 32, 45, 46). It has been observed that whole genome sequencing yields a higher diagnosis rate than exome sequencing alone (18, 47, 48). Notable technological progress has significantly enhanced the diagnostic paradigm (Table 1), facilitated by advanced diagnostic tools (49–52). Early screening of newborns is pivotal for the appropriate implementation of medical interventions and future decision-making (53). The combination of single-cell genome amplification technology and deep sequencing holds promise in elucidating the pathogenesis of additional genetic diseases, thereby enabling high-throughput screening and diagnosis of congenital disabilities and rare diseases (54). Long-read RNA sequencing is also applicable in disorders related to rare diseases (8). However, it is imperative to acknowledge the existence of ethical issues and parental concerns surrounding genomic sequencing (55). One of the primary concerns revolves around informed consent. Parents must comprehensively understand the implications of genetic testing, which may involve discovering incidental findings unrelated to their child’s condition. Such findings could include genetic predispositions to other diseases, which can lead to emotional distress and challenging decisions regarding additional testing and disclosure (56, 57). Furthermore, the potential misuse of genetic information—particularly in employment or insurance contexts—raises significant issues of privacy and discrimination that must be thoughtfully considered (58, 59). Parental views on genomic sequencing are diverse. While some parents regard genetic testing as an essential tool for gaining clarity and accessing specific treatments, others express concerns about the psychological burden it may create. The uncertainty associated with genomic sequencing results—whether they will yield a definitive diagnosis or uncover unknown risks—can provoke feelings of anxiety and helplessness (60, 61). In some instances, parents grapple with the moral dilemma of seeking such testing, fearing they may uncover information they are unprepared to handle, mainly when effective treatments are unavailable (58, 62). Noteworthy attention has been directed toward the application of artificial intelligence (AI) in the diagnosis of rare diseases in recent years (63, 64).

Table 1

Table 1. Recent technological and therapeutic advancement in rare diseases.

Establishing a Clinical Decision Support System (CDSS) utilising Information Retrieval (IR) to aid in the diagnosis of Rare Diseases (RD) presents specific challenges (65). These challenges include catering to physicians’ precise informational needs and ensuring the involvement of domain experts in user-centric development and evaluation (66). Subsequent research endeavors are essential to assess the practical utility of these CDSS in clinical settings. Although tools and resources exist to decipher rare disease variants, aiming to expedite diagnosis and the implementation of timely management strategies, challenges arise in the comprehensive and accurate adoption of specific diagnostic methodologies and in appraising their cost-effectiveness (67, 68). Furthermore, parents encounter difficulties in comprehending the significance of these diagnostic parameters, and reservations and uncertainties exist concerning the application of select diagnostic tools in paediatric cases (69–71).

5 Treatment

There is currently no effective treatment for most rare diseases. Out of the 10,000 reported rare diseases globally, only 5% can be managed with pharmaceutical interventions, underscoring the critical need to enhance patient access to orphan drugs (72). Due to the scarcity of these conditions, the requisite expertise for their management is often limited, resulting in numerous undiagnosed cases and suboptimal treatment regimens among children with rare diseases (73). The rarity of these diseases also complicates the recruitment of an adequate number of patients for clinical trials, posing challenges to the development of effective treatments and cures for many rare diseases (74, 75). Additionally, issues such as low prevalence, limited knowledge of disease progression, and phenotype heterogeneity hinder drug development for rare diseases (76). Other contributing factors include disease severity and the absence of therapeutic alternatives (77). Meanwhile, inadequate healthcare services, unstructured or complex healthcare facilities, and bureaucratic policies hinder access to appropriate medical care or orphan drugs in certain regions. Nonetheless, advancements in prenatal diagnosis and screening hold promise for enhancing diagnostic accuracy and formulating preventive and treatment strategies for paediatric patients with rare diseases (54).

Significant progress has been made in the treatment of rare diseases, particularly those resulting from genetic mutations (Table 1). Advancements encompass CRISPR/Cas9-based gene therapy (78–80), gene therapies (81, 82), RNA-based therapies (83, 84), genetic silencing techniques (85, 86), stem cell therapies (87), immunotherapy (88), molecular-targeted therapies (89, 90), and enzyme replacement therapies (91–94). Personalized medicine is pivotal in addressing rare diseases, with multidisciplinary collaboration holding the potential for tailoring treatments to specific rare diseases (95–97). For instance, there is notable progress in the personalized treatment of Batten’s disease using nusinnersen (98). Additionally, digital health platforms and telemedicine are being explored to expand patients’ treatment accessibility (99, 100).

These developments mirror a rapidly evolving landscape in the rare diseases sphere initiated by state-of-the-art technologies and collaborative endeavors. They offer the prospect of enhancing treatments and overall quality of life for rare disease patients, ushering in renewed hope and improved outcomes. However, their application in paediatric patients with rare diseases remains to be explored.

In addition to traditional funding models for orphan drugs, alternative approaches such as value-based healthcare (VBHC) are increasingly gaining attention (101, 102). Under a value-based model, treatment costs are directly linked to the outcomes achieved, promoting a more efficient allocation of resources and ensuring both efficacy and accessibility of treatments. This model can potentially enhance access to orphan drugs, particularly in resource-constrained settings where the high costs of these treatments can pose significant barriers (103, 104). By focusing on the clinical benefits and long-term outcomes associated with rare disease treatments, value-based healthcare may provide a sustainable solution to the financial burdens linked to rare disease care. Studies, such as those by Fuchs et al., have demonstrated promising results in treating sarcoma patients (105). Furthermore, several countries have reported similar encouraging outcomes when adopting these models (106).

Thus, VBHC signifies a profound transformation in the way healthcare systems approach the management of rare diseases. By prioritising patient-centred outcomes and encouraging collaborative practices, VBHC has the potential to enhance both the quality and effectiveness of care for individuals facing the unique challenges posed by rare conditions. Although challenges in implementation persist, a steadfast commitment to value-based principles can lead to significant improvements in patient outcomes, ultimately benefiting not just individuals but society as a whole (107).

6 Orphan drugs

The pharmaceutical industry’s historically limited focus on orphan drugs has shifted, with a growing recognition of their importance due to market dynamics and technological progress (16). This evolving landscape has prompted diverse business strategies in this expanding sector (108). Orphan drugs are indispensable therapeutic options for individuals with rare conditions, such as cystic fibrosis (CF) (109) and Dunne muscular dystrophy (DMD) (110). Nevertheless, their notably higher costs compared to non-orphan drugs have prompted inquiries into their cost-effectiveness and accessibility. For instance, expenditure on orphan drugs in the United States has surpassed 10%, a figure five times greater than that of non-orphan drugs (111). The utilization of respiratory syncytial virus (RSV) prophylactic programmes for CF patient care generated specific incremental cost-effectiveness ratios and annual budget impacts (112). Treatment of spinal muscular atrophy (SMA) patients with particular drugs led to increased annual costs (113). Consequently, the pricing of select rare disease drugs exceeds international reference prices, rendering most drugs financially unattainable for rare disease patients (114, 115). Apart from the elevated cost of certain orphan drugs, challenges persist in conducting clinical trials for orphan drug research (116).

Notwithstanding these high-cost challenges, several case studies highlight the potential for positive outcomes in the treatment of rare diseases through the application of innovative interventions. For example, the development of CFTR modulators, such as Ivacaftor and Orkambi (Lumacaftor/Ivacaftor), has significantly transformed the treatment landscape for children with cystic fibrosis (CF). Research has shown that these medications improve lung function and nutritional status, resulting in a better quality of life and fewer hospitalisations (117). Another important case is Nusinersen (Spinraza), an antisense oligonucleotide approved for the treatment of spinal muscular atrophy (SMA) in children. Clinical trials have provided evidence that Nusinersen can significantly enhance motor function in infants diagnosed with SMA, contributing to greater independence in their daily activities, enabling them to reach developmental milestones that would have been impossible without treatment (118). Additionally, Idursulfase (Elaprase) represents an enzyme replacement therapy developed for Hunter syndrome (Mucopolysaccharidosis Type II), further illustrating the positive impact of innovative treatments for rare diseases. Clinical studies have shown that idursulfase can enhance walking ability, reduce organ enlargement, and improve the overall quality of life for affected children (119). The approval of these therapies marks a significant advancement in the field of orphan drug development, demonstrating the effectiveness of targeted treatments in enhancing patient outcomes.

Patient organizations and advocacy groups have been instrumental in raising awareness and advocating for access to treatments such as Dornase alfa and Ivacaftor, spearheaded by the Cystic Fibrosis Association of South Africa, which have significantly improved diagnosis rates and the management of cystic fibrosis (CF) patients, resulting in better lung function and a higher quality of life (120). Moreover, the Brazilian Ministry of Health developed a national screening programme for phenylketonuria (PKU), which included access to dietary products and healthcare support for affected families. This initiative has successfully reduced the incidence of cognitive disabilities among treated individuals, highlighting the potential of targeted public health strategies to markedly improve health outcomes (121).

7 The burden of rare diseases in paediatric patients

Rare diseases can significantly impact the quality of life of individuals, leading to physical, emotional, and social stress that detrimentally affects their daily functioning and overall well-being (122–124). The scarcity of these diseases often results in challenges for patients in accessing specialized medical care, treatments, and support services. Furthermore, many rare diseases carry a heightened risk of morbidity and mortality as a result of inadequate and unavailable treatments (124).

The United Nations (UN) recognises the disproportionate impact of rare diseases on individuals, particularly in relation to poverty, discrimination, and work-related adversities (125). This discrimination can significantly affect young individuals, notably in terms of education and social integration. Efforts have been made to establish an economic framework aimed at ameliorating the burden of rare diseases, along with the regulation of orphan drug usage in children (126–128). Yet, individuals living with rare diseases may still face enduring psychological, social, and economic vulnerabilities, encountering specific challenges in education, employment, and social engagements.

7.1 Financial burden

The economic ramifications of rare diseases are substantial, often resulting in additional healthcare expenses and financial hardships for affected families (129–132). Research by Yang et al. (133) in the United States disclosed an estimated total economic burden of $997 billion for 379 rare diseases in 2019. This encompassed direct medical costs of $449 billion (45%), indirect costs of $437 billion (44%), nonmedical costs of $73 billion (7%), and healthcare costs not covered by insurance amounting to $38 billion (4%). In Europe, the estimated expense stood at 147 billion euros, constituting 7.2% of the total pharmaceutical spending (21). The economic burden of rare diseases in Latin America varies across different countries (134). Presently, data are absent regarding the estimated costs of rare diseases in Africa (135). Heinrich et al. (136) put forward an estimated combined cost of €316,990 per patient diagnosed with three distinct rare diseases. Treatment of Fabry disease with enzyme replacement therapy (ERT) escalated the annual economic burden to €9.9 million (137). The estimated economic cost of spinal muscular atrophy (SMA) amounted to CAD$51,796 per patient annually (138), while costs for haemophilia varied across studies (139, 140). López-Bastida et al. (141, 142) reported distinct costs for systemic sclerosis.

The costs associated with rare diseases (RDs) treatment in paediatric patients can present a significant financial burden. The estimated expenditure for paediatric patients is reported at HK$840,908 (US$107,809), which is notably higher than the HK$324,126 (US$41,555) cost for adult patients (123). For instance, the treatment expenses for cystic fibrosis (CF) can escalate up to $300,000 per annum, rendering it one of the most economically demanding chronic diseases within the healthcare spectrum (143). A study conducted in Germany highlighted an approximate mean cost of €17,551, contributing to a national burden of €159 million (144). Additionally, research conducted by Thorat et al. (145) has revealed that annual costs for commercially insured children with CF encompass a wide range: $6,500 to $53,678 for hospitalizations, $20,373 to $47,494 for outpatient prescriptions, and $9,341 to $19,433 for outpatient visits per child. Medicaid-insured children, on the other hand, incur costs ranging from $10,460 to $64,327 for hospitalizations, $13,265 to $45,082 for outpatient prescriptions, and $7,137 to $9,875 for outpatient visits, compared to $5,000 in the comparison group. These findings underscore the substantial financial impact of treating CF patients, even with insurance coverage. Various studies have presented the average annual costs for treating different medical conditions. Specifically, spinal muscular atrophy (SMA) incurred an estimated average total yearly cost of $143,705 per household, with all SMA types incurring an average annual indirect healthcare cost of $63,145 (146). López-Bastida et al. reported an annual average cost of €33,721 for SMA patients (147), while in Germany, the average annual cost of SMA per patient was estimated at €70,566 (148).

The annual economic cost of Duchenne muscular dystrophy (DMD) was estimated at €70,000 in Italy (25) and $46,706 in Australian dollars for children with DMD in Australia (149). For Gaucher disease, the annual economic burden amounted to $48,771, with an individual yearly productivity loss of $1,980 (150) and $3,440,199.2 in India (151). The total annual cost of treating children with beta-thalassemia was estimated at US$127,535 (152), while for transfusion-dependent thalassemia, the cost was estimated at $606,665 (153). Lastly, for Prader-Willi syndrome (PWS), the mean costs were estimated at €58,890 per individual in France (154) and $28,712 in the USA (155).

Thus, the economic impact on paediatric patients with distinct rare diseases varies across countries. Concerns regarding high drug prices and their influence on healthcare expenditure are also prominent (156). While some of these economic costs are not specific to children, given the elevated occurrence of rare diseases in the paediatric population, it is reasonable to surmise that the primary incidence of these costs is among paediatric patients. For illustration, the average hospital cost for treating cystic fibrosis in children amounted to US$26,249.23, in contrast to US$21,600.91 for adults (157). Similarly, Kodra et al. documented a cost of €140,637.30 for children with Cri du Chat syndrome, in comparison to €40,353.25 for adult patients (158), while the medical expenditure for treating phenylketonuria (PKU) was $73,204 in children compared to $40,705 for adult patients (159).

7.2 Physical burden

Numerous rare diseases result in significant physiological dysfunction, leading to chronic pain, fatigue, and decreased mobility, which markedly impede a child’s daily activities (160). Moreover, many rare diseases pose a higher risk of morbidity and mortality compared to common diseases due to the inadequacy and scarcity of treatments (124). Despite improving CF treatment, patients still face physical difficulties (161). Previous research has demonstrated that over 70% of individuals with a rare disease encounter difficulties with daily activities, tasks, motor/sensory functions, and social interactions. Furthermore, more than 42% of patients and caregivers dedicate two hours daily to illness-related tasks such as hygiene, treatment management, housework assistance, and patient mobility (162). Individuals with rare diseases and employed caregivers have specific needs that employers do not consistently address. The ability to request special leave represents a significantly unmet requirement for rare disease patients, as 41% sought leave but did not secure it. The most challenging period pertains to seeking a diagnosis, a process that can encompass approximately six years or longer (163).

7.3 Emotional burden

Rare diseases and their associated symptoms can significantly impact the psychological well-being of children and their families. The profound social isolation experienced by many children with rare diseases often leads to elevated levels of depression, anxiety, and low self-esteem (14). Furthermore, the reliance on medical devices, such as oxygen tanks, can engender feelings of burden and dependency (160).

Families of children with rare diseases also endure considerable emotional strain while navigating the intricate healthcare system, which frequently involves expensive treatments and procedures not covered by insurance (163, 164). Caregiver burden is a common experience as families balance caregiving responsibilities with work and other obligations, often resulting in financial challenges that hinder their quality of life (165, 166). A recent study examining the impact of caring for patients with rare diseases revealed that most respondents (97%) reported caring for children with undiagnosed diseases, with 57% having treated ten such patients throughout their clinical careers. Additionally, almost all paediatricians surveyed (98%) encountered difficulties in caring for children with rare diseases due to delayed diagnosis and a lack of available treatments and clinical guidelines (167).

Caring for a child with a rare disease necessitates a shift in the parental role, leading to emotional stress for the parent/caregiver and behavioral adjustments, including medication administration, data recording, medical appointment attendance, and meeting participation (168). Collectively, these factors place a strain on patients, their caregivers, and healthcare professionals, contributing to negative emotional burdens.

7.4 Social burden

Rare diseases place a financial strain on families and lead to significant social consequences. The stigma associated with having a rare disease can result in social isolation and discrimination, profoundly impacting children’s educational and social development (169, 170). This social ostracism is correlated with a decreased quality of life and increased psychological distress. Many families feel alienated from their communities due to a lack of understanding regarding the complexities of rare diseases (171). A study conducted in Australia surveyed individuals aged 12 to 24 to assess their health and sense of belonging. The results indicated a strong correlation between belonging to marginalized groups and an increase in chronic health issues, heightened psychological distress, and instances of illness or injury that led to absenteeism from school or work (172). This stigma can impede opportunities for social engagement, resulting in emotional distress for both the affected individuals and their families. Children with rare diseases frequently face challenges that affect their academic performance and involvement in school activities, primarily due to the necessity of attending regular medical appointments (173). The emotional impact of living with a rare disease, coupled with concerns about potential discrimination from peers, can result in feelings of isolation and lowered self-esteem among these children. Furthermore, the uncertainty that accompanies rare diseases often leads to emotional distress for both patients and their caregivers. Parents commonly experience anxiety regarding their child’s diagnosis, prognosis, and the availability of effective treatments, which exacerbates their psychological burden. The struggle to manage caregiving duties alongside personal and professional commitments can further strain family dynamics (174–176). Consequently, patients with rare diseases are at a higher risk of social marginalization compared to those without such conditions, resulting in both physiological and psychosocial trauma, thereby increasing the overall social burden on patients and their families.

8 Impact on quality of life

The impact of rare diseases on patients’ quality of life (QoL) is pervasive and often profound. Individuals with rare diseases frequently endure considerable morbidity and mortality, leading to a reduced life expectancy (177, 178). In the case of paediatric patients, they may encounter health-related stigma, bullying, and mental health challenges (174). The intricate nature of rare diseases, delayed diagnoses, and the absence of effective treatments often engender feelings of isolation and psychological distress among patients and their families (126, 179). Assessing health-related quality of life in rare diseases presents unique challenges, but innovative approaches can enhance measurement and clinical outcomes (179). Numerous studies have demonstrated that children with rare diseases exhibit lower quality of life scores than children without chronic diseases (161, 170, 180). As delineated earlier, these diminished quality of life scores are frequently associated with the physical, emotional, and social burdens accompanying rare diseases.

Moreover, the impact of rare diseases on families and caregivers should not be underestimated, as caring for a loved one with a rare disease can be emotionally and financially taxing, often necessitating significant investments of time and resources (131). Parents tending to a child with a rare disease often harbor unmet needs, encompassing dissatisfaction with healthcare professionals’ knowledge, lack of support, financial hardships, social seclusion, and emotional strain (181, 182). Many of these children are susceptible to short- and long-term neurodevelopmental sequelae that can compound adverse psychological quality of life outcomes.

8.1 Physical QoL

Numerous studies have demonstrated the adverse impact of rare diseases on affected children’s physical quality of life. A study focusing on children with rare and undiagnosed diseases revealed that a majority of these individuals experienced limited mobility, leading to difficulties in performing fundamental tasks such as dressing and grooming (183). Similar findings emerged in studies on children with epidermolysis bullosa (184, 185), DMD (186), and Prader-Willi syndrome (187), all of which exhibited decreased physical functioning. While the participation of children with rare diseases in educational settings is deemed advantageous, it presents challenges for the education system and the families involved (173, 188). Moreover, the professional lives of individuals impacted by rare diseases are also significantly affected, with approximately 70% of patients and caregivers having to curtail their professional activities due to factors such as fatigue, memory impairments, time constraints, and commuting difficulties (162).

8.2 Emotional QoL

Children impacted by rare genetic disorders commonly experience anxiety and depression, leading to a diminished quality of life. These children often face increased feelings of loneliness, isolation, and low self-esteem due to their condition (14, 189). Families of affected children undergo emotional turmoil, including feelings of sadness, fear, and frustration. The financial burden associated with treating rare diseases further compounds the challenges faced by affected families (178, 188). Furthermore, studies investigating depression and anxiety in patients with cystic fibrosis (CF) and their caregivers revealed significant increases in depressive symptoms among adolescents, adults, mothers, and fathers. Anxiety levels also rose notably across these same groups (190). Additionally, research has shown a compelling connection between sleep disturbances, depression symptoms in children, and diminished health-related quality of life (HRQOL) in adolescents with CF (180).

Moreover, a study examining the sleep quality of caregivers of patients with Dravet syndrome (DS) found severe sleep impairment in caregivers, often associated with patient anxiety, comorbidities, and sleep disturbances. Notably, caregivers of patients with DS exhibited exacerbated sleep quality issues, anxiety, and depression compared to the general population (191, 192). These findings underscore the significant emotional and psychological toll faced by patients and caregivers of individuals with rare diseases.

8.3 Social QoL

Patients with rare diseases often rely on patient organizations to ameliorate their circumstances and enhance their quality of life. Facilitating active participation in decision-making processes among patients and their families is imperative to mitigate social exclusion (30). The social exclusion linked to rare diseases can diminish affected children’s social quality of life. Several studies have indicated that children with rare diseases exhibit significantly lower levels of social functioning compared to their peers without chronic ailments (188, 193). Moreover, individuals may experience feelings of worthlessness, disadvantage, rejection, stigmatization, and a loss of purpose due to their condition (194). This social exclusion may further curtail involvement in educational and recreational activities, thereby limiting opportunities for social interaction and integration (172). Furthermore, patients with rare diseases often encounter challenges in securing school accommodations, experience absenteeism, and face disruptions in their social and personal lives (178, 195). The compounding of social exclusion is exacerbated by insufficient communication and weak coordination among educators responsible for children diagnosed with rare diseases (196, 197).

Stigma and discrimination represent significant emotional and social challenges for children living with rare diseases. The social stigma associated with these conditions, especially those with visible symptoms, can lead to discrimination and exclusion in social, educational, and healthcare contexts (173). Children with rare diseases are particularly vulnerable, facing difficulties in schools such as bullying, inadequate accommodation, and missed educational opportunities, all of which could hinder their long-term social development (198). In educational settings, these children may struggle to receive appropriate accommodation due to teachers’ unfamiliarity with their conditions. This lack of inclusion can lead to diminished self-esteem and feelings of alienation, which can further impact their academic performance and social growth (199). The repercussions of social exclusion and stigma may be even more pronounced in resource-limited environments (200).

The emotional and social effects of rare diseases on children are intricate and significantly shaped by stigma and discrimination. These challenges often result in feelings of isolation and stress, which can impede their educational and social opportunities and adversely impact their psychosocial well-being (197, 201). Gaining insight into the lived experiences of these children underscores the necessity for comprehensive awareness campaigns and training for educators aimed at fostering inclusivity within schools. By confronting the stigma associated with rare diseases, stakeholders can enhance educational practices and support systems that empower children to flourish academically and socially, thereby alleviating the barriers they face daily. Through collaborative efforts, experiences of stigma can be transformed into opportunities for understanding, acceptance, and community cohesion, ultimately paving the way for a brighter future for children affected by rare conditions (199, 202).

8.4 Parental/caregiver burden and quality of life

Despite the growing attention toward patients with rare diseases, insufficient focus has been placed on the role of parents as caregivers for affected children within the healthcare system and health research. The impact of rare diseases in childhood and adolescence on the psychosocial dynamics of a family is substantial, as these conditions necessitate a high level of care and disease management from the affected families (193, 203). A recent study showed that 45.5% of caregivers reported feelings of care overload, 43% reported coping poorly due to stress, as well as experiencing anguish toward the role of caregiving for children with RDs. While most respondents declared that their entire life was subordinated to the role of caregiver (62.5%), 60.5% felt others did not understand them, and 51.5% believed that their needs were unimportant to others (204).

Variations exist within families regarding the care provided to children with chronic or rare illnesses, which can significantly influence the quality of life of affected patients, contingent upon parental involvement (193, 205). A systematic review indicates that parents of children with rare diseases experience a compromised quality of life compared to standard values and parents of children with other chronic conditions. Results reveal that 75.6% of participants encountered stigmatization, with nearly half (46.4%) reporting instances of bullying indicative of low to moderate self-care skills in social activities and peer relationships. Additionally, 43.9% highlighted mental health issues in their children, while some parents expressed dissatisfaction with the efforts of educators in addressing bullying (174, 175).

A recent systematic review has elucidated the increased economic burden on caregivers of individuals with cystic fibrosis, as well as the lower quality of life utility scores, elevated prevalence of depression and anxiety among caregivers, and reduced caregiver productivity (206). Similarly, caregivers of boys with Duchenne muscular dystrophy (DMD) encounter comparable economic burdens and diminished quality of life (207). Parents of children with chronic illnesses demonstrate a decreased psychological and physical quality of life compared to parents of healthy children. Moreover, caregivers of patients with DMD appear to exhibit prolonged longevity owing to enhanced treatment and management strategies (129, 186), increasing parents’ or caregivers’ burden, thus impacting their quality of life. Caregivers of patients with Dravet syndrome (DS) also face intricate psychosocial challenges (192). Furthermore, the illness of a child may lead to a familial breakdown, and a single parent raising a child may be confronted with heightened difficulty and responsibility, thereby intensifying psychological trauma for both the parents and the child. Consequently, the prioritization of psychological aid for patients with rare diseases and their caregivers is emphasized (30, 164).

9 Public health policy and rare diseases

The management of rare diseases necessitates a comprehensive public health strategy that incorporates policy development, resource allocation, and the active involvement of diverse stakeholders, including healthcare providers, researchers, and patient advocacy groups (208, 209). Public health policy is vital for the adequate care and management of rare diseases, particularly in ensuring that sufficient resources are earmarked for diagnosis, treatment, and long-term care.

In recent years, international frameworks have emerged to advance the rights of individuals with rare diseases. A notable milestone was the passage of the United Nations General Assembly resolution A/RES/78/173 in 2021, which calls for heightened attention to the global challenges posed by rare diseases. This resolution encourages member states to formulate national plans for rare diseases, improve access to diagnostic tools, and foster research into treatments. Furthermore, it emphasises the crucial need for international collaboration and the sharing of information to tackle the public health challenges associated with rare diseases (210). These initiatives underscore the significance of integrating considerations for rare diseases into public health policy to ensure that individuals with these conditions are not marginalized. Furthermore, value-based healthcare models, which focus on patient outcomes and cost-effectiveness, can be instrumental in facilitating access to essential treatments, including orphan drugs (103, 211). Implementing educational initiatives designed to raise awareness of rare diseases among healthcare professionals and the general public is critical for reducing diagnostic delays and enhancing care (107).

Patient advocacy groups are essential in influencing public health policy regarding rare diseases. These organizations offer invaluable insights into patient needs, promote awareness, and advocate for policy changes that emphasize research and funding for rare diseases (212). Collaborative efforts between advocacy groups and governmental bodies can significantly improve the quality of care and support available to families affected by rare diseases.

Successful policy models in countries such as the USA and members of the European Union demonstrate that integrating rare disease management into national health systems is not only feasible but can also lead to significant improvements in patient outcomes (213–215). Recently, Latin America has introduced policies and recommendations aimed at enhancing access to equitable healthcare services for patients with rare diseases (216). These models typically involve the establishment of national registries, coordination among healthcare providers, and the formation of public-private partnerships to ensure sustainable access to care and treatment. For instance, initiatives like the European Reference Networks (ERNs) create platforms for sharing best practices and fostering collective learning among healthcare providers across Europe (217). By prioritising cooperation, countries can collaborate to promote data sharing, advance clinical research, and develop innovative treatment options that extend beyond their borders.

Investing in registry-based research can yield valuable insights into rare diseases by enabling the systematic collection of data that informs policy decisions. These registries facilitate longitudinal studies that evaluate treatment outcomes and patient experiences, thereby generating the essential evidence needed to develop informed guidelines and optimize resource allocation (218, 219). While data scarcity and healthcare disparities persist, significant opportunities exist for improvement and innovation (220). Therefore, public health policies play a crucial role in enhancing the circumstances of children with rare diseases. By focusing on accessibility, advocacy, funding, and education, public health initiatives can improve the quality of life for affected families and promote advancements in research and treatment. A coordinated global effort that prioritises rare diseases will be vital in addressing the ongoing challenges faced by this vulnerable population.

10 Challenges

Rare diseases pose a significant global challenge for individuals, families, and the healthcare system (Table 2) (221). The heterogeneity of epidemiological approaches and inconsistent reporting constrained the identification of high-quality population-based studies and data collection. The generalisability of results to other regions may be compromised by including solely global, European, or American data (22, 123).

Table 2

Table 2. Challenges faced by patients and their families with rare diseases.

Numerous obstacles hinder rare disease research, such as an inadequate understanding of rare diseases’ pathophysiology and natural history, along with a lack of incentives to fund the development of orphan drugs for small populations (222). Furthermore, innovative treatments may not be readily available to the general population due to factors including pricing and reimbursement decisions and the limited commercial interest of some pharmaceutical companies in investing in new orphan drug research (13, 195). An additional challenge arises in developing innovative approaches to clinical trials and health technology assessment methods in small populations, as well as the absence of aggregated primary data for estimating the reliable economic burden of rare diseases (223, 224). For instance, many African countries do not maintain national registries for rare diseases, complicating efforts to track their prevalence and fully understand the issue (225, 226). Many regions lack essential diagnostic tools, such as genomic sequencing, which can result in misdiagnoses or delays in diagnosing children with rare diseases (227, 228). Healthcare systems in numerous Latin American countries face similar challenges due to insufficient data on rare diseases, lengthy waiting times for diagnostic tests, and limited public awareness (5, 229). As a result, families often struggle to navigate the myriad medical and social challenges posed by rare diseases. Disparities in the quality of care and access to treatment for rare diseases persist across social classes and communities, even in developed economies with advanced rare disease policies, budgets, and clinical guidelines (21). Variations in the availability and accessibility of medical treatment between rural and urban areas may necessitate long-distance travel for treatment. This socio-economic divide between urban and rural areas exacerbates these challenges, as rural families have less access to medical services. There is also minimal public health education regarding rare diseases, leading to misconceptions and stigma within local communities (135, 226, 230). The development of orphan drugs for rare diseases also encounters notable challenges (231). The cost of certain available orphan drugs is prohibitively high, and many countries lack adequate insurance coverage for rare diseases, preventing families from accessing vital treatments (232).

Accessing social benefits and financial support for rare diseases has presented challenges for many individuals, particularly concerning the high costs of specialized care and treatment, especially for children diagnosed with rare diseases. Those suffering from rare diseases often experience pain, loneliness, and susceptibility to misinformation throughout the diagnosis and treatment process (36). One significant barrier to effective care in regions like Latin America is the limited access to specialized healthcare professionals (216), lack of communication between care professionals and uncoordinated appointments (233). Specialized paediatricians play a pivotal role in identifying, diagnosing, and treating children with rare diseases. It is alarming that a mere 5.3% of surveyed doctors in China were found to be knowledgeable about rare diseases (234). Similarly, a study in Australia attributed approximately 30% of diagnostic delays among families to a lack of knowledge among health professionals (167); with similar findings in Poland, where parents complained about doctors’ lack of knowledge (235). The aforementioned lack of awareness extends beyond healthcare professionals to include families, caregivers, education professionals, and peer groups, all of whom possess a limited understanding of rare diseases and their impact on the quality of life and socioeconomic burden in children (173, 236).

Therefore, comprehensive support systems are essential to address these challenges. These may encompass financial assistance, mental health services, educational support, and access to advanced therapies (Table 3). Additionally, increased research funding and policy changes are imperative to better cater to the needs of patients with rare diseases and their families, ultimately alleviating their disease burden and enhancing their overall quality of life.

Table 3

Table 3. Recommendations for improving the diagnosis and treatment of patients with rare diseases.

By implementing these recommendations, healthcare systems can significantly enhance the diagnosis and treatment of rare diseases, thereby improving the quality of life for patients and their families.

11 Future research directions

Several strategies and policies have been established to enhance awareness of rare diseases and facilitate the dissemination of pertinent information within the healthcare community, particularly within the EU (166, 223). These initiatives encompass the development of rare disease registries (17, 76), active involvement of patients in research decision-making (237), application of health utility estimation techniques (238), creation of a regulatory framework and initiatives for the development of orphan drugs (127, 239), as well as the establishment of advocacy groups (240). Despite these advancements, the practical implementation of these strategies and policies remains a challenge. Therefore, it is imperative for stakeholders and policymakers to take actionable steps to implement these policies (Table 4). These actionable policy initiatives include but are not limited to:

Table 4

Table 4. Recommendations for policymakers in improving the diagnosis and treatment of patients with rare diseases.

11.1 Multidisciplinary care models

Governments and healthcare providers need to prioritize the implementation of multidisciplinary care models. These models should integrate the expertise of specialists, general practitioners, psychologists, social workers, and various other healthcare professionals to offer comprehensive care. Evidence has shown that such coordinated approaches enhance patient outcomes by addressing the physical, emotional, and social needs of those living with rare diseases (7, 241). For example, the Netherlands has successfully adopted a multidisciplinary strategy through the Dutch Rare Disease Registry, significantly improving patients’ quality of life and their access to vital treatments (242). The registry is not only significant for local healthcare systems but also plays a crucial role in broader initiatives across Europe aimed at gathering data on rare diseases. This integration enables stakeholders to make well-informed decisions. By prioritising standardized data collection and sharing, the registry strengthens the reliability of research efforts and the treatment protocols derived from the gathered information (243).

11.2 Expanding access to orphan drugs

A significant challenge in the treatment of rare diseases lies in the high cost and limited availability of orphan drugs. Policymakers should focus on developing strategies to improve access to these essential medications, particularly in resource-constrained environments. One potential approach is the establishment of public-private partnerships involving governments, pharmaceutical companies, and non-profit organizations to share the financial burden associated with orphan drug development. Furthermore, it is crucial to create frameworks for price negotiation that would make orphan drugs more affordable, especially for low- and middle-income countries (244–246).

11.3 Global cooperation and data sharing

There is an urgent need for enhanced international collaboration in the research and treatment of rare diseases. By developing global data-sharing platforms, countries can pool their resources, conduct larger-scale studies, improve diagnostic capabilities, and accelerate the development of orphan drugs (212, 247, 248). The success of initiatives like the European Reference Networks (ERNs), which aim to improve healthcare for rare disease patients across Europe, should serve as a model for global implementation (217). Each European Reference Network (ERN) consists of a minimum of ten healthcare providers from at least eight different member states, ensuring a diverse pool of expertise and resources (249). Beyond their role in patient care, ERNs are instrumental in advancing research related to rare diseases. By pooling clinical data and sharing findings, they contribute to the establishment of registries that enhance our understanding of disease trajectories, treatment efficacy, and patient outcomes. This collaborative research is crucial, as it provides the evidence necessary to develop new therapies and improve standards of care (250). Embracing ideas such as the Findable, Accessible, Interoperable, and Reusable (FAIR) principles could facilitate better cross-border collaboration and data sharing, fostering innovative research and application of solutions in clinical settings (251).

The practical implementation of these measures will address the immediate and long-term needs of those affected and contribute to sustained progress in rare disease care and research. Furthermore, future research endeavors should prioritize specific areas to gain a deeper understanding of the true impact of rare diseases on the quality of life in paediatric patients, as detailed in Table 5. By focusing on these prospective research directions, the scientific community can advance its knowledge, enhance clinical outcomes, and improve the lives of patients and families impacted by rare diseases. Collaborative efforts transcending disciplines and borders will be indispensable in overcoming the complexities and substantial challenges associated with these conditions.

Table 5

Table 5. Future research directions.

12 Conclusion

Rare diseases present a considerable global burden, impacting millions of individuals worldwide, with children constituting the most affected demographic. Inadequacies in disease prevalence estimates underscore significant gaps in our understanding of the epidemiology of rare diseases, particularly within the paediatric cohort. The persistent nature of numerous rare diseases imposes substantial physical, emotional, and social burdens on affected children and their families, profoundly affecting their quality of life. These challenges are further exacerbated by the absence of suitable and accessible treatments for various rare diseases, resulting in numerous children remaining undiagnosed or receiving suboptimal care. The profound ramifications for the quality of life of affected children and their families underscore the imperative to develop efficacious treatments and enhance healthcare accessibility to alleviate the disproportionate burden imposed by these conditions.

Author contributions

JSD: Conceptualization, Data curation, Formal analysis, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review & editing. CZ: Conceptualization, Data curation, Formal analysis, Methodology, Visualization, Writing – original draft, Writing – review & editing. LD: Data curation, Formal analysis, Resources, Validation, Writing – original draft, Writing – review & editing. YL: Data curation, Formal analysis, Supervision, Visualization, Writing – original draft, Writing – review & editing. XC: Data curation, Formal analysis, Validation, Visualization, Writing – original draft, Writing – review & editing. BA: Conceptualization, Data curation, Formal analysis, Validation, Visualization, Writing – original draft, Writing – review & editing. JL: Conceptualization, Funding acquisition, Methodology, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the National Natural Science Foundation of China (82260665).

Acknowledgments

The authors are grateful to the High-Level Scientific Research Startup Funding, Affiliated Hospital of Guangdong Medical University (1057z20230003, 1057z20230042).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Gen AI was used in the creation of this manuscript.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Abbreviations

CF, Cystic fibrosis; DMD, Duchenne muscular dystrophy; DS, Drave syndrome; ERT, Enzyme replacement therapy; HRQoL, Health-related quality of life; NGS, Next-generation sequencing; PWS, Prader-Willi syndrome; PKU, Phenylketonuria; QoL, Quality of life; RDs, Rare diseases; SMA, Spinal muscular atrophy; WES, Whole-exome sequencing; WGS, Whole-genome sequencing.

References

1. Abozaid, GM, Kerr, K, McKnight, A, and Al-Omar, HA. Criteria to define rare diseases and orphan drugs: a systematic review protocol. BMJ Open. (2022) 12:e062126. doi: 10.1136/bmjopen-2022-062126

PubMed Abstract | Crossref Full Text | Google Scholar

2. Raycheva, R, Kostadinov, K, Mitova, E, Bogoeva, N, Iskrov, G, Stefanov, G, et al. Challenges in mapping European rare disease databases, relevant for ML-based screening technologies in terms of organizational, FAIR and legal principles: scoping review. Front Public Health. (2023) 11:1214766. doi: 10.3389/fpubh.2023.1214766

PubMed Abstract | Crossref Full Text | Google Scholar

3. Vicente, E, Pruneda, L, and Ardanaz, E. Regarding the estimations of people affected by rare diseases. Eur J Hum Genet. (2021) 29:1032–3. doi: 10.1038/s41431-020-00763-z

PubMed Abstract | Crossref Full Text | Google Scholar

4. Cheung, RY, Cohen, JC, and Illingworth, P. Orphan drug policies: implications for the United States, Canada, and developing countries. Health Law J. (2004) 12:183–200.

PubMed Abstract | Google Scholar

5. Giugliani, R, Castillo Taucher, S, Hafez, S, Oliveira, JB, Rico-Restrepo, M, Rozenfeld, P, et al. Opportunities and challenges for newborn screening and early diagnosis of rare diseases in Latin America. Front Genet. (2022) 13:1053559. doi: 10.3389/fgene.2022.1053559

Crossref Full Text | Google Scholar

6. Rare Diseases International. (2025). Vision & Mission. Available online at: https://www.rarediseasesinternational.org/vision-mission/ (Accessed January 18, 2025).

Google Scholar

7. Patterson, AM, O’Boyle, M, VanNoy, GE, and Dies, KA. Emerging roles and opportunities for rare disease patient advocacy groups. Ther Adv Rare Dis. (2023) 4:26330040231164425. doi: 10.1177/26330040231164425

PubMed Abstract | Crossref Full Text | Google Scholar

8. Marwaha, S, Knowles, JW, and Ashley, EA. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med. (2022) 14:23. doi: 10.1186/s13073-022-01026-w

PubMed Abstract | Crossref Full Text | Google Scholar

9. Schaaf, J, Sedlmayr, M, Schaefer, J, and Storf, H. Diagnosis of rare diseases: a scoping review of clinical decision support systems. Orphanet J Rare Dis. (2020) 15:263. doi: 10.1186/s13023-020-01536-z

PubMed Abstract | Crossref Full Text | Google Scholar

10. D’Angelo, CS, Hermes, A, McMaster, CR, Prichep, E, Richer, É, Van Der Westhuizen, FH, et al. Barriers and considerations for diagnosing rare diseases in indigenous populations. Front Pediatr. (2020) 8:579924. doi: 10.3389/fped.2020.579924

PubMed Abstract | Crossref Full Text | Google Scholar

11. Hsu, JC, Wu, HC, Feng, WC, Chou, CH, Lai, ECC, and Lu, CY. Disease and economic burden for rare diseases in Taiwan: a longitudinal study using Taiwan’s National Health Insurance Research Database. PLoS One. (2018) 13:e0204206. doi: 10.1371/journal.pone.0204206

Crossref Full Text | Google Scholar

12. Tsitsani, P, Katsaras, G, and Soteriades, ES. Barriers to and facilitators of providing Care for Adolescents Suffering from rare diseases: a mixed systematic review. Pediatr Rep. (2023) 15:462–82. doi: 10.3390/pediatric15030043

PubMed Abstract | Crossref Full Text | Google Scholar

13. Klimova, B, Storek, M, Valis, M, and Kuca, K. Global view on rare diseases: a Mini review. Curr Med Chem. (2017) 24:3153–3158. doi: 10.2174/0929867324666170511111803

Crossref Full Text | Google Scholar

14. Somanadhan, S, O’Donnell, R, Bracken, S, McNulty, S, Sweeney, A, O’Toole, D, et al. Children and young people’s experiences of living with rare diseases: an integrative review. J Pediatr Nurs. (2023) 68:e16–26. doi: 10.1016/j.pedn.2022.10.014

PubMed Abstract | Crossref Full Text | Google Scholar

15. Boettcher, J, Boettcher, M, Wiegand-Grefe, S, and Zapf, H. Being the pillar for children with rare diseases-a systematic review on parental quality of life. Int J Environ Res Public Health. (2021) 18:4993. doi: 10.3390/ijerph18094993

PubMed Abstract | Crossref Full Text | Google Scholar

16. Mingorance, A. Drivers of orphan drug development. ACS Med Chem Lett. (2018) 9:962–4. doi: 10.1021/acsmedchemlett.8b00438

PubMed Abstract | Crossref Full Text | Google Scholar

17. Ruseckaite, R, Mudunna, C, Caruso, M, Helwani, F, Millis, N, Lacaze, P, et al. Current state of rare disease registries and databases in Australia: a scoping review. Orphanet J Rare Dis. (2023) 18:216. doi: 10.1186/s13023-023-02823-1

PubMed Abstract | Crossref Full Text | Google Scholar

18. Martinussen, J, Chalk, M, Elliott, J, and Gallacher, L. Receiving genomic sequencing results through the Victorian undiagnosed disease program: exploring parental experiences. J Pers Med. (2022) 12:1250. doi: 10.3390/jpm12081250

PubMed Abstract | Crossref Full Text | Google Scholar

19. Liu, J, Yu, Y, Zhong, M, Ma, C, and Shao, R. Long way to go: Progress of orphan drug accessibility in China from 2017 to 2022. Front Pharmacol. (2023) 14:1138996. doi: 10.3389/fphar.2023.1138996

PubMed Abstract | Crossref Full Text | Google Scholar

20. Guo, J, Liu, P, Chen, L, Lv, H, Li, J, Yu, W, et al. National Rare Diseases Registry System (NRDRS): China’s first nation-wide rare diseases demographic analyses. Orphanet J Rare Dis. (2021) 16:515. doi: 10.1186/s13023-021-02130-7

PubMed Abstract | Crossref Full Text | Google Scholar

21. Adachi, T, El-Hattab, AW, Jain, R, Nogales Crespo, KA, Quirland Lazo, CI, Scarpa, M, et al. Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges. Int J Environ Res Public Health. (2023) 20:4732. doi: 10.3390/ijerph20064732

PubMed Abstract | Crossref Full Text | Google Scholar

22. Nguengang Wakap, S, Lambert, DM, Olry, A, Rodwell, C, Gueydan, C, Lanneau, V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet EJHG. (2020) 28:165–73. doi: 10.1038/s41431-019-0508-0

PubMed Abstract | Crossref Full Text | Google Scholar

23. Bush, A, Chitty, L, Harcourt, J, Hewitt, RJ, and Nicholson, AG. Congenital lung disease In: R. W. Wilmott, R. Deterding, A. Li, F. Ratjen, P. Sly, H. J. Zar et al. (Eds). Kendig’s Disorders of the Respiratory Tract in Children (9th Edn), Elsevier (2019). 289–337.e8. doi: 10.1016/B978-0-323-44887-1.00018-3

Crossref Full Text | Google Scholar

24. Rafeeq, MM, and Murad, HAS. Cystic fibrosis: current therapeutic targets and future approaches. J Transl Med. (2017) 15:84. doi: 10.1186/s12967-017-1193-9

PubMed Abstract | Crossref Full Text | Google Scholar

25. Orso, M, Migliore, A, Polistena, B, Russo, E, Gatto, F, Monterubbianesi, M, et al. Duchenne muscular dystrophy in Italy: a systematic review of epidemiology, quality of life, treatment adherence, and economic impact. PLoS One. (2023) 18:e0287774. doi: 10.1371/journal.pone.0287774

PubMed Abstract | Crossref Full Text | Google Scholar

26. Kozel, BA, Barak, B, Ae Kim, C, Mervis, CB, Osborne, LR, Porter, M, et al. Williams syndrome. Nat Rev Dis Primer. (2021) 7:42. doi: 10.1038/s41572-021-00276-z

PubMed Abstract | Crossref Full Text | Google Scholar

27. Cheema, HA, Waheed, N, and Saeed, A. Unusual case of juvenile Tay-Sachs disease. BMJ Case Rep. (2019) 12:e230140. doi: 10.1136/bcr-2019-230140

PubMed Abstract | Crossref Full Text | Google Scholar

28. Vidal, S, Xiol, C, Pascual-Alonso, A, O’Callaghan, M, Pineda, M, and Armstrong, J. Genetic landscape of Rett syndrome Spectrum: improvements and challenges. Int J Mol Sci. (2019) 20:3925. doi: 10.3390/ijms20163925

PubMed Abstract | Crossref Full Text | Google Scholar

29. Gonzalo, S, Kreienkamp, R, and Askjaer, P. Hutchinson-Gilford progeria syndrome: a premature aging disease caused by LMNA gene mutations. Ageing Res Rev. (2017) 33:18–29. doi: 10.1016/j.arr.2016.06.007

PubMed Abstract | Crossref Full Text | Google Scholar

30. Borski, K. Characteristics of rare diseases. Gen Intern Med Clin Innov. (2017) 2:3–4. doi: 10.15761/GIMCI.1000142

Crossref Full Text | Google Scholar

31. Tripathy, K, and Nanda, T. The influence of environmental and genetic factors on various disorders and diseases. J Genet Syndr Gene Ther. (2011) 2. doi: 10.4172/2157-7412.S11-001

Crossref Full Text | Google Scholar

32. Ren, ZM, Li, WJ, Xing, ZH, Fu, XY, Zhang, JY, Chen, YS, et al. Detecting rare thalassemia in children with anemia using third-generation sequencing. Hematol Amst Neth. (2023) 28:2241226. doi: 10.1080/16078454.2023.2241226

PubMed Abstract | Crossref Full Text | Google Scholar

33. Tukker, AM, Royal, CD, Bowman, AB, and McAllister, KA. The impact of environmental factors on monogenic Mendelian diseases. Toxicol Sci Off J Soc Toxicol. (2021) 181:3–12. doi: 10.1093/toxsci/kfab022

PubMed Abstract | Crossref Full Text | Google Scholar

34. Lazareva, TE, Barbitoff, YA, Nasykhova, YA, Pavlova, NS, Bogaychuk, PM, and Glotov, AS. Statistical dissection of the genetic determinants of phenotypic heterogeneity in genes with multiple associated rare diseases. Genes. (2023) 14:2100. doi: 10.3390/genes14112100

PubMed Abstract | Crossref Full Text | Google Scholar

35. Zhu, CY, Hong, W, Wang, L, Ding, LJ, and Zhang, X. Department of health sciences, National Natural Science Foundation of China, Beijing 100085, China, et al. towards key scientific questions in the diagnosis and treatment of rare diseases: summary from the 297th meeting of the Shuangqing forum. Zool Res. (2022) 43:234–6. doi: 10.24272/j.issn.2095-8137.2022.068

PubMed Abstract | Crossref Full Text | Google Scholar

36. Tirado Perez, IS, Lopez, SP, and Zarate Vergara, AC. Rare diseases: a current view. J Pediatr Care. (2017) 3. doi: 10.21767/2471-805X.100031

Crossref Full Text | Google Scholar

37. Rillig, F, Grüters, A, Schramm, C, and Krude, H. The interdisciplinary diagnosis of rare diseases. Dtsch Arzteblatt Int. (2022) 119:469–75. doi: 10.3238/arztebl.m2022.0219

Crossref Full Text | Google Scholar

38. Austin, CP, Cutillo, CM, Lau, LPL, Jonker, AH, Rath, A, Julkowska, D, et al. Future of rare diseases research 2017-2027: an IRDiRC perspective. Clin Transl Sci. (2018) 11:21–7. doi: 10.1111/cts.12500

PubMed Abstract | Crossref Full Text | Google Scholar

39. Taruscio, D, Floridia, G, Salvatore, M, Groft, SC, and Gahl, WA. Undiagnosed diseases: Italy-US collaboration and international efforts to tackle rare and common diseases lacking a diagnosis In: M Posada De La Paz, D Taruscio, and SC Groft, editors. Rare diseases epidemiology: Update and overview. Cham: Springer International Publishing (2017). 25–38.

Google Scholar

40. 100,000 Genomes Project Pilot InvestigatorsSmedley, D, Smith, KR, Martin, A, Thomas, EA, McDonagh, EM, et al. 100,000 genomes pilot on rare-disease diagnosis in health care — preliminary report. N Engl J Med. (2021) 385:1868–80. doi: 10.1056/NEJMoa2035790

PubMed Abstract | Crossref Full Text | Google Scholar

41. Licata, L, Via, A, Turina, P, Babbi, G, Benevenuta, S, Carta, C, et al. Resources and tools for rare disease variant interpretation. Front Mol Biosci. (2023) 10:1169109. doi: 10.3389/fmolb.2023.1169109

PubMed Abstract | Crossref Full Text | Google Scholar

42. Bavisetty, S, Grody, WW, and Yazdani, S. Emergence of pediatric rare diseases: review of present policies and opportunities for improvement. Rare Dis. (2013) 1:e23579. doi: 10.4161/rdis.23579

PubMed Abstract | Crossref Full Text | Google Scholar

43. Faye, F, Crocione, C, Anido de Peña, R, Bellagambi, S, Escati Peñaloza, L, Hunter, A, et al. Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a rare barometer retrospective patient survey. Eur J Hum Genet EJHG. (2024) 32:1116–26. doi: 10.1038/s41431-024-01604-z

PubMed Abstract | Crossref Full Text | Google Scholar

44. Maver, A, Lohmann, K, Borovečki, F, Wolstenholme, N, Taylor, RL, Spielmann, M, et al. Quality assurance for next-generation sequencing diagnostics of rare neurological diseases in the European reference network. Eur J Hum Genet EJHG. (2024) 32:1014–21. doi: 10.1038/s41431-024-01639-2

PubMed Abstract | Crossref Full Text | Google Scholar

45. Frésard, L, and Montgomery, SB. Diagnosing rare diseases after the exome. Mol Case Stud. (2018) 4:a003392. doi: 10.1101/mcs.a003392

PubMed Abstract | Crossref Full Text | Google Scholar

46. Fu, MP, Merrill, SM, Sharma, M, Gibson, WT, Turvey, SE, and Kobor, MS. Rare diseases of epigenetic origin: challenges and opportunities. Front Genet. (2023) 14:1113086. doi: 10.3389/fgene.2023.1113086

Crossref Full Text | Google Scholar

47. Wright, CF, FitzPatrick, DR, and Firth, HV. Paediatric genomics: diagnosing rare disease in children. Nat Rev Genet. (2018) 19:253–68. doi: 10.1038/nrg.2017.116

PubMed Abstract | Crossref Full Text | Google Scholar

48. Huang, X, Wu, D, Zhu, L, Wang, W, Yang, R, Yang, J, et al. Application of a next-generation sequencing (NGS) panel in newborn screening efficiently identifies inborn disorders of neonates. Orphanet J Rare Dis. (2022) 17:66. doi: 10.1186/s13023-022-02231-x

PubMed Abstract | Crossref Full Text | Google Scholar

49. Hou, YCC, Yu, HC, Martin, R, Cirulli, ET, Schenker-Ahmed, NM, Hicks, M, et al. Precision medicine integrating whole-genome sequencing, comprehensive metabolomics, and advanced imaging. Proc Natl Acad Sci USA. (2020) 117:3053–62. doi: 10.1073/pnas.1909378117

PubMed Abstract | Crossref Full Text | Google Scholar

50. Pawliński, Ł, Tobór, E, Suski, M, Biela, M, Polus, A, and Kieć-Wilk, B. Proteomic biomarkers in Gaucher disease. J Clin Pathol. (2021) 74:25–9. doi: 10.1136/jclinpath-2020-206580

PubMed Abstract | Crossref Full Text | Google Scholar

51. Kolb, SJ, Coffey, CS, Yankey, JW, Krosschell, K, Arnold, WD, Rutkove, SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. (2017) 82:883–91. doi: 10.1002/ana.25101

PubMed Abstract | Crossref Full Text | Google Scholar

52. Bax, BE. Biomarkers in rare diseases. Int J Mol Sci. (2021) 22:673. doi: 10.3390/ijms22020673

PubMed Abstract | Crossref Full Text | Google Scholar

53. Ferlini, A, Gross, ES, and Garnier, N. Rare diseases’ genetic newborn screening as the gateway to future genomic medicine: the Screen4Care EU-IMI project. Orphanet J Rare Dis. (2023) 4:310. doi: 10.1186/s13023-023-02916-x

Crossref Full Text | Google Scholar

54. Zhao, H, Du, C, Yang, G, and Wang, Y. Diagnosis, treatment, and research status of rare diseases related to birth defects. Intractable Rare Dis Res. (2023) 12:148–60. doi: 10.5582/irdr.2023.01052

PubMed Abstract | Crossref Full Text | Google Scholar

55. Martin, S, Angolini, E, Audi, J, Bertini, E, Bruno, LP, Coulter, J, et al. Patient preferences in genetic newborn screening for rare diseases: study protocol. BMJ Open. (2024) 14:e081835. doi: 10.1136/bmjopen-2023-081835

PubMed Abstract | Crossref Full Text | Google Scholar

56. Wong, CS, Kogon, AJ, Warady, BA, Furth, SL, Lantos, JD, and Wilfond, BS. Ethical and policy considerations for genomic testing in pediatric research: the path toward disclosing individual research results. Am J Kidney Dis Off J Natl Kidney Found. (2019) 73:837–45. doi: 10.1053/j.ajkd.2019.01.020

PubMed Abstract | Crossref Full Text | Google Scholar

57. Kilkku, N, and Halkoaho, A. Informed consent, genomic research and mental health: a integrative review. Nurs Ethics. (2022) 29:973–87. doi: 10.1177/09697330211066573

PubMed Abstract | Crossref Full Text | Google Scholar

58. Kruse, J, Mueller, R, Aghdassi, AA, Lerch, MM, and Salloch, S. Genetic testing for rare diseases: a systematic review of ethical aspects. Front Genet. (2021) 12:701988. doi: 10.3389/fgene.2021.701988

PubMed Abstract | Crossref Full Text | Google Scholar

59. Rodriguez-Monguio, R, Spargo, T, and Seoane-Vazquez, E. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? Orphanet J Rare Dis. (2017) 12:1. doi: 10.1186/s13023-016-0551-7

PubMed Abstract | Crossref Full Text | Google Scholar

60. Brett, GR, Martyn, M, Lynch, F, de Silva, MG, Ayres, S, Gallacher, L, et al. Parental experiences of ultrarapid genomic testing for their critically unwell infants and children. Genet Med. (2020) 22:1976–85. doi: 10.1038/s41436-020-0912-4

PubMed Abstract | Crossref Full Text | Google Scholar

61. Chediak, L, Bedlington, N, Gadson, A, Kent, A, Khalek, AA, Rosen, L, et al. Unlocking sociocultural and community factors for the global adoption of genomic medicine. Orphanet J Rare Dis. (2022) 17:191. doi: 10.1186/s13023-022-02328-3

PubMed Abstract | Crossref Full Text | Google Scholar

62. Lewis, C, Sanderson, S, Hill, M, Patch, C, Searle, B, Hunter, A, et al. Parents’ motivations, concerns and understanding of genome sequencing: a qualitative interview study. Eur J Hum Genet. (2020) 28:874–84. doi: 10.1038/s41431-020-0575-2

PubMed Abstract | Crossref Full Text | Google Scholar

63. Abdallah, S, Sharifa, M, Almadhoun, MK, Khawar, MM, Shaikh, U, Balabel, KM, et al. The impact of artificial intelligence on optimizing diagnosis and treatment plans for rare genetic disorders. Cureus. 15:e46860

Google Scholar

64. Wojtara, M, Rana, E, Rahman, T, Khanna, P, and Singh, H. Artificial intelligence in rare disease diagnosis and treatment. Clin Transl Sci. (2023) 16:2106–11. doi: 10.1111/cts.13619

PubMed Abstract | Crossref Full Text | Google Scholar

65. Schaaf, J, Prokosch, HU, Boeker, M, Schaefer, J, Vasseur, J, Storf, H, et al. Interviews with experts in rare diseases for the development of clinical decision support system software - a qualitative study. BMC Med Inform Decis Mak. (2020) 20:230. doi: 10.1186/s12911-020-01254-3

PubMed Abstract | Crossref Full Text | Google Scholar

66. Schaaf, J, Sedlmayr, M, Sedlmayr, B, Prokosch, HU, and Storf, H. Evaluation of a clinical decision support system for rare diseases: a qualitative study. BMC Med Inform Decis Mak. (2021) 21:65. doi: 10.1186/s12911-021-01435-8

PubMed Abstract | Crossref Full Text | Google Scholar

67. Ferket, BS, Baldwin, Z, Murali, P, Pai, A, Mittendorf, KF, Russell, HV, et al. Cost-effectiveness frameworks for comparing genome and exome sequencing versus conventional diagnostic pathways: a scoping review and recommended methods. Genet Med Off J Am Coll Med Genet. (2022) 24:2014–27. doi: 10.1016/j.gim.2022.06.004

PubMed Abstract | Crossref Full Text | Google Scholar

68. Lavelle, TA, Feng, X, Keisler, M, Cohen, JT, Neumann, PJ, Prichard, D, et al. Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions. Genet Med Off J Am Coll Med Genet. (2022) 24:1349–61. doi: 10.1016/j.gim.2022.03.005

PubMed Abstract | Crossref Full Text | Google Scholar

69. Chassagne, A, Pélissier, A, Houdayer, F, Cretin, E, Gautier, E, Salvi, D, et al. Exome sequencing in clinical settings: preferences and experiences of parents of children with rare diseases (SEQUAPRE study). Eur J Hum Genet EJHG. (2019) 27:701–10. doi: 10.1038/s41431-018-0332-y

PubMed Abstract | Crossref Full Text | Google Scholar

70. Elliott, AM. Genetic counseling and genome sequencing in pediatric rare disease. Cold Spring Harb Perspect Med. (2020) 10:a036632. doi: 10.1101/cshperspect.a036632

PubMed Abstract | Crossref Full Text | Google Scholar

71. Crellin, E, Martyn, M, McClaren, B, and Gaff, C. What matters to parents? A scoping review of parents’ service experiences and needs regarding genetic testing for rare diseases. Eur J Hum Genet EJHG. (2023) 31:869–78. doi: 10.1038/s41431-023-01376-y

PubMed Abstract | Crossref Full Text | Google Scholar

72. Qiao, L, Liu, X, Shang, J, Zuo, W, Xu, T, Qu, J, et al. Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges. Orphanet J Rare Dis. (2022) 17:352. doi: 10.1186/s13023-022-02507-2

PubMed Abstract | Crossref Full Text | Google Scholar

73. Narayanan, S, Mainz, JG, Gala, S, Tabori, H, and Grossoehme, D. Adherence to therapies in cystic fibrosis: a targeted literature review. Expert Rev Respir Med. (2017) 11:129–45. doi: 10.1080/17476348.2017.1280399

PubMed Abstract | Crossref Full Text | Google Scholar

74. Groft, SC, Posada, M, and Taruscio, D. Progress, challenges and global approaches to rare diseases. Acta Paediatr. (2021) 110:2711–6. doi: 10.1111/apa.15974

PubMed Abstract | Crossref Full Text | Google Scholar

75. Cortial, L, Nguyen, C, Julkowska, D, Cocqueel-Tiran, F, Moliner, AM, Blin, O, et al. Managing rare diseases: examples of national approaches in Europe, North America and East Asia. Rare Dis Orphan Drugs J. (2022) 1:10. doi: 10.20517/rdodj.2022.02

Crossref Full Text | Google Scholar

76. Jansen-van der Weide, MC, Gaasterland, CMW, Roes, KCB, Pontes, C, Vives, R, Sancho, A, et al. Rare disease registries: potential applications towards impact on development of new drug treatments. Orphanet J Rare Dis. (2018) 13. doi: 10.1186/s13023-018-0836-0

PubMed Abstract | Crossref Full Text | Google Scholar

77. Dabbous, O, Chachoua, L, Aballéa, S, Sivignon, M, Persson, U, Petrou, S, et al. Valuation of treatments for rare diseases: a systematic literature review of societal preference studies. Adv Ther. (2023) 40:393–424. doi: 10.1007/s12325-022-02359-z

PubMed Abstract | Crossref Full Text | Google Scholar

78. Frangoul, H, Altshuler, D, Cappellini, MD, Chen, YS, Domm, J, Eustace, BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. (2021) 384:252–60. doi: 10.1056/NEJMoa2031054

PubMed Abstract | Crossref Full Text | Google Scholar

79. Gillmore, JD, Gane, E, Taubel, J, Kao, J, Fontana, M, Maitland, ML, et al. CRISPR-Cas9 in Vivo gene editing for transthyretin amyloidosis. N Engl J Med. (2021) 385:493–502. doi: 10.1056/NEJMoa2107454

PubMed Abstract | Crossref Full Text | Google Scholar

80. Pavan, E, Ormazabal, M, Peruzzo, P, Vaena, E, Rozenfeld, P, and Dardis, A. CRISPR/Cas9 editing for Gaucher disease modelling. Int J Mol Sci. (2020) 21:3268. doi: 10.3390/ijms21093268

PubMed Abstract | Crossref Full Text | Google Scholar

81. Papaioannou, I, Owen, JS, and Yáñez-Muñoz, RJ. Clinical applications of gene therapy for rare diseases: a review. Int J Exp Pathol. (2023) 104:154–76. doi: 10.1111/iep.12478

PubMed Abstract | Crossref Full Text | Google Scholar

82. Jensen, TL, Gøtzsche, CR, and Woldbye, DPD. Current and future prospects for gene therapy for rare genetic diseases affecting the brain and spinal cord. Front Mol Neurosci. (2021) 14:695937. doi: 10.3389/fnmol.2021.695937

PubMed Abstract | Crossref Full Text | Google Scholar

83. Zogg, H, Singh, R, and Ro, S. Current advances in RNA therapeutics for human diseases. Int J Mol Sci. (2022) 23:2736. doi: 10.3390/ijms23052736

PubMed Abstract | Crossref Full Text | Google Scholar

84. Mercuri, E, Darras, BT, Chiriboga, CA, Day, JW, Campbell, C, Connolly, AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. (2018) 378:625–35. doi: 10.1056/NEJMoa1710504

PubMed Abstract | Crossref Full Text | Google Scholar

85. Adams, D, Gonzalez-Duarte, A, O’Riordan, WD, Yang, CC, Ueda, M, Kristen, AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. (2018) 379:11–21. doi: 10.1056/NEJMoa1716153

PubMed Abstract | Crossref Full Text | Google Scholar

86. Aghajanian, H, Rurik, JG, and Epstein, JA. CAR-based therapies: opportunities for immuno-medicine beyond cancer. Nat Metab. (2022) 4:163–9. doi: 10.1038/s42255-022-00537-5

PubMed Abstract | Crossref Full Text | Google Scholar

87. Hoang, DM, Pham, PT, Bach, TQ, Ngo, ATL, Nguyen, QT, Phan, TTK, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. (2022) 7:1–41. doi: 10.1038/s41392-022-01134-4

PubMed Abstract | Crossref Full Text | Google Scholar

88. Motte, J, Sgodzai, M, Schneider-Gold, C, Steckel, N, Mika, T, Hegelmaier, T, et al. Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. Neuron. (2024) 112:1757–1763.e2. doi: 10.1016/j.neuron.2024.04.014

PubMed Abstract | Crossref Full Text | Google Scholar

89. Staedtke, V, Anstett, K, Bedwell, D, Giovannini, M, Keeling, K, Kesterson, R, et al. Gene-targeted therapy for neurofibromatosis and schwannomatosis: the path to clinical trials. Clin Trials Lond Engl. (2024) 21:51–66. doi: 10.1177/17407745231207970

PubMed Abstract | Crossref Full Text | Google Scholar

90. De Boeck, K, and Amaral, MD. Progress in therapies for cystic fibrosis. Lancet Respir Med. (2016) 4:662–74. doi: 10.1016/S2213-2600(16)00023-0

Crossref Full Text | Google Scholar

91. Jameson, E, Jones, S, and Remmington, T. Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I. Cochrane Database Syst Rev. (2019) 2021. doi: 10.1002/14651858.CD009354.pub5

PubMed Abstract | Crossref Full Text | Google Scholar

92. Sims, KB, Pastores, GM, Weinreb, NJ, Barranger, J, Rosenbloom, BE, Packman, S, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet. (2008) 73:430–40. doi: 10.1111/j.1399-0004.2008.00978.x

PubMed Abstract | Crossref Full Text | Google Scholar

93. Ditters, IAM, van der Beek, NAME, Brusse, E, van der Ploeg, AT, van den Hout, JMP, and Huidekoper, HH. Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study. Orphanet J Rare Dis. (2023) 18:108. doi: 10.1186/s13023-023-02715-4

PubMed Abstract | Crossref Full Text | Google Scholar

94. De Vivo, DC, Bertini, E, Swoboda, KJ, Hwu, WL, Crawford TOFinkel, RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord NMD. (2019) 29:842–56. doi: 10.1016/j.nmd.2019.09.007

PubMed Abstract | Crossref Full Text | Google Scholar

95. Drilon, A, Laetsch, TW, Kummar, S, DuBois, SG, Lassen, UN, Demetri, GD, et al. Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. (2018) 378:731–9. doi: 10.1056/NEJMoa1714448

PubMed Abstract | Crossref Full Text | Google Scholar

96. van Eeghen, AM, Bruining, H, Wolf, NI, Bergen, AA, Houtkooper, RH, van Haelst, MM, et al. Personalized medicine for rare neurogenetic disorders: can we make it happen? Cold Spring Harb Mol Case Stud. (2022) 8:a006200. doi: 10.1101/mcs.a006200

Crossref Full Text | Google Scholar

97. Scarpa, M, Ceci, A, Tomanin, R, Mincarone, P, and Begley, D. Personalised medicine in paediatrics: individualising treatment in children with rare neurological diseases. EPMA J. (2011) 2:231–9. doi: 10.1007/s13167-011-0081-2

PubMed Abstract | Crossref Full Text | Google Scholar

98. Kim, J, Hu, C, Moufawad El Achkar, C, Black, LE, Douville, J, Larson, A, et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med. (2019) 381:1644–52. doi: 10.1056/NEJMoa1813279

PubMed Abstract | Crossref Full Text | Google Scholar

99. Gerk, A, Kundu, S, Meara, JG, and Stegmann, J. Digital solutions for rare diseases in global health. Lancet Glob Health. (2024) 12:e1091. doi: 10.1016/S2214-109X(24)00189-X

PubMed Abstract | Crossref Full Text | Google Scholar

100. Senyel, D, Senn, K, Boyd, J, and Nagels, K. A systematic review of telemedicine for neuromuscular diseases: components and determinants of practice. BMC Digit Health. (2024) 2:17. doi: 10.1186/s44247-024-00078-9

Crossref Full Text | Google Scholar

101. Pian, JMY, Owusu, N, Vitarello, J, Yan, WX, Lo, AW, and Yu, TW. How to pay for individualized genetic medicines. Nat Med. (2024) 30:1816–8. doi: 10.1038/s41591-024-03071-x

PubMed Abstract | Crossref Full Text | Google Scholar

102. Fernández-Salido, M, Alhambra-Borrás, T, Casanova, G, and Garcés-Ferrer, J. Value-based healthcare delivery: a scoping review. Int J Environ Res Public Health. (2024) 21:134. doi: 10.3390/ijerph21020134

PubMed Abstract | Crossref Full Text | Google Scholar

103. Venema, A, Peeks, F, Rossi, A, Jager, EA, and Derks, TGJ. Towards values-based healthcare for inherited metabolic disorders: an overview of current practices for persons with liver glycogen storage disease and fatty acid oxidation disorders. J Inherit Metab Dis. (2022) 45:1018–27. doi: 10.1002/jimd.12555

PubMed Abstract | Crossref Full Text | Google Scholar

104. He, W, Li, M, Cao, L, Liu, R, You, J, Jing, F, et al. Introducing value-based healthcare perspectives into hospital performance assessment: a scoping review. J Evid-Based Med. (2023) 16:200–15. doi: 10.1111/jebm.12534

PubMed Abstract | Crossref Full Text | Google Scholar

105. Fuchs, B, and Heesen, PSwissSarcomaNetwork. From data integration to precision medicine: a value-based healthcare approach for sarcoma care. J Clin Med. (2024). doi: 10.3390/jcm13216500

PubMed Abstract | Crossref Full Text | Google Scholar

106. Alnaqbi, KA, Elezbawy, B, Fasseeh, AN, Bangash, AR, Elshamy, A, Shendi, H, et al. Development of the emirates multi-criteria decision analysis tool for orphan drugs. Cureus. (2024) 16:e55215. doi: 10.7759/cureus.55215

PubMed Abstract | Crossref Full Text | Google Scholar

107. Teisberg, E, Wallace, S, and O’Hara, S. Defining and implementing value-based health care: a strategic framework. Acad Med. (2020) 95:682–5. doi: 10.1097/ACM.0000000000003122

PubMed Abstract | Crossref Full Text | Google Scholar

108. Bolislis, WR, Corriol-Rohou, S, Hill-Venning, C, Hoogland, H, Joos, A, King, D, et al. Orphan medicines for pediatric use: a focus on the European Union. Clin Ther. (2019) 41:2630–42. doi: 10.1016/j.clinthera.2019.10.006

PubMed Abstract | Crossref Full Text | Google Scholar

109. Jones, JT, Morelli, KA, Vesely, EM, Puerner, CTS, Pavuluri, CK, Ross, BS, et al. The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of Aspergillus fumigatus biofilms. MBio. (2023) 14. doi: 10.1128/mbio.01516-23

PubMed Abstract | Crossref Full Text | Google Scholar

110. Servais, L, Mercuri, E, Straub, V, Guglieri, M, Seferian, AM, Scoto, M, et al. Long-term safety and efficacy data of Golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1/2 trial. Nucleic Acid Ther. (2022) 32:29–39. doi: 10.1089/nat.2021.0043

PubMed Abstract | Crossref Full Text | Google Scholar

111. Chambers, JD, Silver, MC, Berklein, FC, Cohen, JT, and Neumann, PJ. Orphan drugs offer larger health gains but less favorable cost-effectiveness than non-orphan drugs. J Gen Intern Med. (2020) 35:2629–36. doi: 10.1007/s11606-020-05805-2

PubMed Abstract | Crossref Full Text | Google Scholar

112. McGirr, AA, Schwartz, KL, Allen, U, Solomon, M, and Sander, B. The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: a decision analysis model. Hum Vaccin Immunother. (2017) 13:599–606. doi: 10.1080/21645515.2016.1235670

PubMed Abstract | Crossref Full Text | Google Scholar

113. Toro, W, Yang, M, Georgieva, M, Song, W, Patel, A, Jiang, AX, et al. Health care resource utilization and costs for patients with spinal muscular atrophy: findings from a retrospective US claims database analysis. Adv Ther. (2023) 40:4589–605. doi: 10.1007/s12325-023-02621-y

PubMed Abstract | Crossref Full Text | Google Scholar

114. Mu, Y, Song, K, and Song, Y. A Cross-sectional study of Price and affordability of drugs for rare diseases in Shandong Province, China. Int J Environ Res Public Health. (2022) 19:13319. doi: 10.3390/ijerph192013319

PubMed Abstract | Crossref Full Text | Google Scholar

115. Villa, F, Di Filippo, A, Pierantozzi, A, Genazzani, A, Addis, A, Trifirò, G, et al. Orphan drug prices and epidemiology of rare diseases: a Cross-sectional study in Italy in the years 2014–2019. Front Med. (2022) 9:820757. doi: 10.3389/fmed.2022.820757

PubMed Abstract | Crossref Full Text | Google Scholar

116. Spagnolo, P, and Du Bois, RM. The challenges of clinical research in orphan diseases In: V Cottin, JF Cordier, and L Richeldi, editors. Orphan lung diseases. London: Springer London (2015). 5–15.

Google Scholar

117. Whiting, P, Al, M, Burgers, L, Westwood, M, Ryder, S, Hoogendoorn, M, et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess Winch Engl. (2014) 18:1–106. doi: 10.3310/hta18180

PubMed Abstract | Crossref Full Text | Google Scholar

118. Finkel, RS, Mercuri, E, Darras, BT, Connolly, AM, Kuntz, NL, Kirschner, J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. (2017) 377:1723–32. doi: 10.1056/NEJMoa1702752

PubMed Abstract | Crossref Full Text | Google Scholar

119. Ueda, K, and Hokugo, J. Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan. Expert Opin Drug Saf. (2020) 19:891–901. doi: 10.1080/14740338.2020.1751120

PubMed Abstract | Crossref Full Text | Google Scholar

120. Zampoli, M, Verstraete, J, Frauendorf, M, Kassanjee, R, Workman, L, Morrow, BM, et al. Cystic fibrosis in South Africa: spectrum of disease and determinants of outcome. ERJ Open Res. (2021) 7:00856–2020. doi: 10.1183/23120541.00856-2020

PubMed Abstract | Crossref Full Text | Google Scholar

121. Ramalho, ARO, Ramalho, RJR, Oliveira, CRP, Magalhães, MMGS, Santos, EG, Sarmento, PMP, et al. Evaluation of effectiveness and outcome of PKU screening and management in the state of Sergipe. Brazil Arq Bras Endocrinol Metabol. (2014) 58:62–7. doi: 10.1590/0004-2730000002885

PubMed Abstract | Crossref Full Text | Google Scholar

122. Angelis, A, Tordrup, D, and Kanavos, P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. (2015) 119:964–79. doi: 10.1016/j.healthpol.2014.12.016

PubMed Abstract | Crossref Full Text | Google Scholar

123. Chung, CCY, Ng, NYT, Ng, YNC, Lui, ACY, Fung, JLF, Chan, MCY, et al. Socio-economic costs of rare diseases and the risk of financial hardship: a cross-sectional study. Lancet Reg Health West Pac. (2023) 34:100711. doi: 10.1016/j.lanwpc.2023.100711

PubMed Abstract | Crossref Full Text | Google Scholar

124. Sequeira, AR, Mentzakis, E, Archangelidi, O, and Paolucci, F. The economic and health impact of rare diseases: a meta-analysis. Health Policy Technol. (2021) 10:32–44. doi: 10.1016/j.hlpt.2021.02.002

Crossref Full Text | Google Scholar

125. Velvin, G, Dammann, B, Haagensen, T, Johansen, H, Strømme, H, Geirdal, AØ, et al. Work participation in adults with rare genetic diseases - a scoping review. BMC Public Health. 23:910. doi: 10.1186/s12889-023-15654-3

PubMed Abstract | Crossref Full Text | Google Scholar

126. Currie, GR, Gerber, B, Lorenzetti, D, MacDonald, K, Benseler, SM, Bernier, FP, et al. Developing a framework of cost elements of socioeconomic burden of rare disease: a scoping review. PharmacoEconomics. (2023) 41:803–18. doi: 10.1007/s40273-023-01262-x

PubMed Abstract | Crossref Full Text | Google Scholar

127. Epps, C, Bax, R, Croker, A, Green, D, Gropman, A, Klein, AV, et al. Global regulatory and public health initiatives to advance pediatric drug development for rare diseases. Ther Innov Regul Sci. (2022) 56:964–75. doi: 10.1007/s43441-022-00409-w

PubMed Abstract | Crossref Full Text | Google Scholar

128. Durairaj, C, and Bhattacharya, I. Challenges, approaches and enablers: effectively triangulating towards dose selection in pediatric rare diseases. J Pharmacokinet Pharmacodyn. (2023) 50:445–59. doi: 10.1007/s10928-023-09868-6

PubMed Abstract | Crossref Full Text | Google Scholar

129. Schreiber-Katz, O, Klug, C, Thiele, S, Schorling, E, Zowe, J, Reilich, P, et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. (2014) 9:210. doi: 10.1186/s13023-014-0210-9

PubMed Abstract | Crossref Full Text | Google Scholar

130. Angelis, A, Kanavos, P, López-Bastida, J, Linertová, R, Oliva-Moreno, J, Serrano-Aguilar, P, et al. Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. Eur J Health Econ HEPAC Health Econ Prev Care. (2016) 17:31–42. doi: 10.1007/s10198-016-0783-4

PubMed Abstract | Crossref Full Text | Google Scholar

131. López-Bastida, J, Oliva-Moreno, J, Linertová, R, and Serrano-Aguilar, P. Social/economic costs and health-related quality of life in patients with rare diseases in Europe. Eur J Health Econ. (2016) 17:1–5. doi: 10.1007/s10198-016-0780-7

PubMed Abstract | Crossref Full Text | Google Scholar

132. Iskrov, G, Astigarraga, I, Stefanov, R, López-Bastida, J, Linertová, R, Oliva-Moreno, J, et al. Social/economic costs and health-related quality of life in patients with histiocytosis in Europe. Eur J Health Econ HEPAC Health Econ Prev Care. (2016) 17:67–78. doi: 10.1007/s10198-016-0790-5

PubMed Abstract | Crossref Full Text | Google Scholar

133. Yang, G, Cintina, I, Pariser, A, Oehrlein, E, Sullivan, J, and Kennedy, A. The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. (2022) 17:163. doi: 10.1186/s13023-022-02299-5

PubMed Abstract | Crossref Full Text | Google Scholar

134. Dias, AG, Daher, A, Barrera Ortiz, L, Carreño-Moreno, S, Hafez, HSR, Jansen, AM, et al. Rarecare: a policy perspective on the burden of rare diseases on caregivers in Latin America. Front Public Health. (2023) 11:1127713. doi: 10.3389/fpubh.2023.1127713

PubMed Abstract | Crossref Full Text | Google Scholar

135. Luzzatto, L, and Makani, J. Treating rare diseases in Africa: the drugs exist but the need is unmet. Front Pharmacol. (2022) 12:770640. doi: 10.3389/fphar.2021.770640

PubMed Abstract | Crossref Full Text | Google Scholar

136. Heinrich, F, Cordts, I, Günther, R, Stolte, B, Zeller, D, Schröter, C, et al. Economic evaluation of motor neuron diseases: a nationwide cross-sectional analysis in Germany. J Neurol. (2023) 270:4922–38. doi: 10.1007/s00415-023-11811-1

PubMed Abstract | Crossref Full Text | Google Scholar

137. Rombach, SM, Hollak, CE, Linthorst, GE, and Dijkgraaf, MG. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J Rare Dis. (2013) 8:29. doi: 10.1186/1750-1172-8-29

PubMed Abstract | Crossref Full Text | Google Scholar

138. McMillan, HJ, Gerber, B, Cowling, T, Khuu, W, Mayer, M, Wu, JW, et al. Burden of spinal muscular atrophy (SMA) on patients and caregivers in Canada. J Neuromuscul Dis. (2021) 8:553–68. doi: 10.3233/JND-200610

PubMed Abstract | Crossref Full Text | Google Scholar

139. Kodra, Y, Cavazza, M, Schieppati, A, De Santis, M, Armeni, P, Arcieri, R, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus. (2014) 12:s567–75. doi: 10.2450/2014.0042-14s

PubMed Abstract | Crossref Full Text | Google Scholar

140. Rodriguez-Santana, I, DasMahapatra, P, Burke, T, Hakimi, Z, Bartelt-Hofer, J, Nazir, J, et al. Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study. Orphanet J Rare Dis. (2022) 17:150. doi: 10.1186/s13023-022-02301-0

PubMed Abstract | Crossref Full Text | Google Scholar

141. López-Bastida, J, Linertová, R, Oliva-Moreno, J, Serrano-Aguilar, P, Posada-de-la-Paz, M, Kanavos, P, et al. Social/economic costs and health-related quality of life in patients with scleroderma in Europe. Eur J Health Econ HEPAC Health Econ Prev Care. (2016) 17:109–17. doi: 10.1007/s10198-016-0789-y

PubMed Abstract | Crossref Full Text | Google Scholar

142. López-Bastida, J, Linertová, R, Oliva-Moreno, J, Posada-de-la-Paz, M, and Serrano-Aguilar, P. Social economic costs and health-related quality of life in patients with systemic sclerosis in Spain. Arthritis Care Res. (2014) 66:473–80. doi: 10.1002/acr.22167

PubMed Abstract | Crossref Full Text | Google Scholar

143. Leso, V, Romano, R, Santocono, C, Caruso, M, Iacotucci, P, Carnovale, V, et al. The impact of cystic fibrosis on the working life of patients: a systematic review. J Cyst Fibros. (2022) 21:361–9. doi: 10.1016/j.jcf.2021.08.011

PubMed Abstract | Crossref Full Text | Google Scholar

144. Frey, S, Stargardt, T, Schneider, U, and Schreyögg, J. The economic burden of cystic fibrosis in Germany from a payer perspective. PharmacoEconomics. (2019) 37:1029–39. doi: 10.1007/s40273-019-00797-2

Crossref Full Text | Google Scholar

145. Thorat, T, McGarry, LJ, Bonafede, MM, Limone, BL, Rubin, JL, Jariwala-Parikh, K, et al. Healthcare resource utilization and costs among children with cystic fibrosis in the United States. Pediatr Pulmonol. (2021) 56:2833–44. doi: 10.1002/ppul.25535

PubMed Abstract | Crossref Full Text | Google Scholar

146. Chambers, GM, Settumba, SN, Carey, KA, Cairns, A, Menezes, MP, Ryan, M, et al. Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy. Neurology. (2020) 95:e1–e10. doi: 10.1212/WNL.0000000000009715

PubMed Abstract | Crossref Full Text | Google Scholar

147. López-Bastida, J, Peña-Longobardo, LM, Aranda-Reneo, I, Tizzano, E, Sefton, M, and Oliva-Moreno, J. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. (2017) 12:141. doi: 10.1186/s13023-017-0695-0

PubMed Abstract | Crossref Full Text | Google Scholar

148. Klug, C, Schreiber-Katz, O, Thiele, S, Schorling, E, Zowe, J, Reilich, P, et al. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. (2016) 11:58. doi: 10.1186/s13023-016-0424-0

PubMed Abstract | Crossref Full Text | Google Scholar

149. Teoh, LJ, Geelhoed, EA, Bayley, K, Leonard, H, and Laing, NG. Health care utilization and costs for children and adults with duchenne muscular dystrophy. Muscle Nerve. (2016) 53:877–84. doi: 10.1002/mus.24965

PubMed Abstract | Crossref Full Text | Google Scholar

150. Qi, X, Xu, J, Shan, L, Li, Y, Cui, Y, Liu, H, et al. Economic burden and health related quality of life of ultra-rare Gaucher disease in China. Orphanet J Rare Dis. (2021) 16:358. doi: 10.1186/s13023-021-01963-6

PubMed Abstract | Crossref Full Text | Google Scholar

151. Mhatre, SP, Muranjan, M, and Gogtay, NJ. Economic burden of Gaucher disease at a tertiary care public Hospital in Mumbai. Indian J Pediatr. (2024) 91:463–9. doi: 10.1007/s12098-023-04740-4

PubMed Abstract | Crossref Full Text | Google Scholar

152. Uchil, A, Muranjan, M, and Gogtay, NJ. Economic burden of beta-thalassaemia major receiving hypertransfusion therapy at a public hospital in Mumbai. Natl Med J India. (2023) 36:11–6. doi: 10.25259/NMJI_580_20

PubMed Abstract | Crossref Full Text | Google Scholar

153. Shafie, AA, Wong, JHY, Ibrahim, HM, Mohammed, NS, and Chhabra, IK. Economic burden in the management of transfusion-dependent thalassaemia patients in Malaysia from a societal perspective. Orphanet J Rare Dis. (2021) 16:157. doi: 10.1186/s13023-021-01791-8

PubMed Abstract | Crossref Full Text | Google Scholar

154. Chevreul, K, Berg Brigham, K, Clément, MC, Poitou, C, and Tauber, M. Members of the BURQOL-RD research network listed in the online appendix. Economic burden and health-related quality of life associated with Prader-Willi syndrome in France. J Intellect Disabil Res JIDR. (2016) 60:879–90. doi: 10.1111/jir.12288

PubMed Abstract | Crossref Full Text | Google Scholar

155. Shoffstall, AJ, Gaebler, JA, Kreher, NC, Niecko, T, Douglas, D, Strong, TV, et al. The high direct medical costs of Prader-Willi syndrome. J Pediatr. (2016) 175:137–43. doi: 10.1016/j.jpeds.2016.05.018

PubMed Abstract | Crossref Full Text | Google Scholar

156. Stella, P, and Gold-von, SG. Pharmaceutical pricing, cost containment and new treatments for rare diseases in children. Orphanet J Rare Dis. (2014) 9:152. doi: 10.1186/s13023-014-0152-2

PubMed Abstract | Crossref Full Text | Google Scholar

157. Vadagam, P, and Kamal, KM. Hospitalization costs of cystic fibrosis in the United States: a retrospective analysis. Hosp Pract. (1995) 46:203–13. doi: 10.1080/21548331.2018.1505407

PubMed Abstract | Crossref Full Text | Google Scholar

158. Kodra, Y, Cavazza, M, de Santis, M, Guala, A, Liverani, ME, Armeni, P, et al. Social economic costs, health-related quality of life and disability in patients with cri Du chat syndrome. Int J Environ Res Public Health. (2020) 17:5951. doi: 10.3390/ijerph17165951

PubMed Abstract | Crossref Full Text | Google Scholar

159. Rose, AM, Grosse, SD, Garcia, SP, Bach, J, Kleyn, M, Simon, NJE, et al. The financial and time burden associated with phenylketonuria treatment in the United States. Mol Genet Metab Rep. (2019) 21:100523. doi: 10.1016/j.ymgmr.2019.100523

PubMed Abstract | Crossref Full Text | Google Scholar

160. Rajmil, L, Perestelo-Pérez, L, and Herdman, M. Quality of life and rare diseases In: M Posada De La Paz and SC Groft, editors. Rare diseases epidemiology, vol. 686. Dordrecht: Springer Netherlands (2010). 251–72.

Google Scholar

161. Hurley, N, Moyna, NM, Kehoe, B, McCaffrey, N, Redmond, K, and Hardcastle, SJ. Factors influencing physical activity in adults with cystic fibrosis. BMC Pulm Med. (2021) 21:113. doi: 10.1186/s12890-021-01482-x

PubMed Abstract | Crossref Full Text | Google Scholar

162. Quinn, L, Playle, R, Drew, CJG, Taiyari, K, Williams-Thomas, R, Muratori, LM, et al. Physical activity and exercise outcomes in Huntington’s disease (PACE-HD): results of a 12-month trial-within-cohort feasibility study of a physical activity intervention in people with Huntington’s disease. Parkinsonism Relat Disord. (2022) 101:75–89. doi: 10.1016/j.parkreldis.2022.06.013

PubMed Abstract | Crossref Full Text | Google Scholar

163. Vitale, SA. Individual and family issues surrounding a rare disease. Clin Nurs Stud. (2017) 6:45. doi: 10.5430/cns.v6n1p45

Crossref Full Text | Google Scholar

164. Kenny, T, Bogart, K, Freedman, A, Garthwaite, C, Henley, S, Bolz-Johnson, M, et al. The importance of psychological support for parents and caregivers of children with a rare disease at diagnosis. Rare Dis Orphan Drugs J. (2022) 1:7. doi: 10.20517/rdodj.2022.04

Crossref Full Text | Google Scholar

165. Schuller, Y, Hollak, CEM, and Biegstraaten, M. The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review. Orphanet J Rare Dis. (2015) 10:92. doi: 10.1186/s13023-015-0305-y

PubMed Abstract | Crossref Full Text | Google Scholar

166. Cannizzo, S, Lorenzoni, V, Palla, I, Pirri, S, Trieste, L, Triulzi, I, et al. Rare diseases under different levels of economic analysis: current activities, challenges and perspectives. RMD Open. (2018) 4:e000794. doi: 10.1136/rmdopen-2018-000794

PubMed Abstract | Crossref Full Text | Google Scholar

167. Zurynski, Y, Gonzalez, A, Deverell, M, Phu, A, Leonard, H, Christodoulou, J, et al. Rare disease: a national survey of paediatricians’ experiences and needs. BMJ Paediatr Open. (2017) 1:e000172. doi: 10.1136/bmjpo-2017-000172

PubMed Abstract | Crossref Full Text | Google Scholar

168. Gómez-Zúñiga, B, Pulido, R, Pousada, M, and Armayones, M. The role of parent/caregiver with children affected by rare diseases: navigating between love and fear. Int J Environ Res Public Health. (2021) 18:3724. doi: 10.3390/ijerph18073724

PubMed Abstract | Crossref Full Text | Google Scholar

169. Currie, G, and Szabo, J. Social isolation and exclusion: the parents’ experience of caring for children with rare neurodevelopmental disorders. Int J Qual Stud Health Well-Being. (2020) 15:1725362. doi: 10.1080/17482631.2020.1725362

PubMed Abstract | Crossref Full Text | Google Scholar

170. Bogart, K, Hemmesch, A, Barnes, E, Blissenbach, T, Beisang, A, Engel, P, et al. Healthcare access, satisfaction, and health-related quality of life among children and adults with rare diseases. Orphanet J Rare Dis. (2022) 17:196. doi: 10.1186/s13023-022-02343-4

PubMed Abstract | Crossref Full Text | Google Scholar

171. Atkins, JC, and Padgett, CR. Living with a rare disease: psychosocial impacts for parents and family members – a systematic review. J Child Fam Stud. (2024) 33:617–36. doi: 10.1007/s10826-024-02790-6

Crossref Full Text | Google Scholar

172. Robards, F, Kang, M, Luscombe, G, Hawke, C, Sanci, L, Steinbeck, K, et al. Intersectionality: social marginalisation and self-reported health status in young people. Int J Environ Res Public Health. (2020) 17:8104. doi: 10.3390/ijerph17218104

PubMed Abstract | Crossref Full Text | Google Scholar

173. Paz-Lourido, B, Negre, F, De La Iglesia, B, and Verger, S. Influence of schooling on the health-related quality of life of children with rare diseases. Health Qual Life Outcomes. (2020) 18:109. doi: 10.1186/s12955-020-01351-x

PubMed Abstract | Crossref Full Text | Google Scholar

174. Adama, EA, Arabiat, D, Foster, MJ, Afrifa-Yamoah, E, Runions, K, Vithiatharan, R, et al. The psychosocial impact of rare diseases among children and adolescents attending mainstream schools in Western Australia. Int J Incl Educ. (2023) 27:1273–86. doi: 10.1080/13603116.2021.1888323

Crossref Full Text | Google Scholar

175. Foster, M, Adama, E, Arabiat, D, Runions, K, Vithiatharan, R, Zgambo, M, et al. Parents’ experiences of children with a rare disease attending a mainstream school: Australia. J Pediatr Nurs. (2022) 63:e50–7. doi: 10.1016/j.pedn.2021.10.013

PubMed Abstract | Crossref Full Text | Google Scholar

176. Baynam, G, Gomez, R, and Jain, R. Stigma associated with genetic testing for rare diseases—causes and recommendations. Front Genet. (2024) 15:1335768. doi: 10.3389/fgene.2024.1335768

PubMed Abstract | Crossref Full Text | Google Scholar

177. Puiu, M, and Dan, D. Rare diseases, from European resolutions and recommendations to actual measures and strategies. Maedica. (2010) 5:128–31.

PubMed Abstract | Google Scholar

178. Evans, WR, and Rafi, I. Rare diseases in general practice: recognising the zebras among the horses. Br J Gen Pract. (2016) 66:550–1. doi: 10.3399/bjgp16X687625

PubMed Abstract | Crossref Full Text | Google Scholar

179. Lenderking, WR, Anatchkova, M, Pokrzywinski, R, Skalicky, A, Martin, ML, and Gelhorn, H. Measuring health-related quality of life in patients with rare disease. J Patient Rep Outcomes. (2021) 5:61. doi: 10.1186/s41687-021-00336-8

PubMed Abstract | Crossref Full Text | Google Scholar

180. Vandeleur, M, Walter, LM, Armstrong, DS, Robinson, P, Nixon, GM, and Horne, RSC. Quality of life and mood in children with cystic fibrosis: associations with sleep quality. J Cyst Fibros Off J Eur Cyst Fibros Soc. (2018) 17:811–20. doi: 10.1016/j.jcf.2017.11.021

PubMed Abstract | Crossref Full Text | Google Scholar

181. Pelentsov, LJ, Fielder, AL, Laws, TA, and Esterman, AJ. The supportive care needs of parents with a child with a rare disease: results of an online survey. BMC Fam Pract. (2016) 17:88. doi: 10.1186/s12875-016-0488-x

PubMed Abstract | Crossref Full Text | Google Scholar

182. Mcmullan, J, Lohfeld, L, and McKnight, AJ. Needs of informal caregivers of people with a rare disease: a rapid review of the literature. BMJ Open. (2022) 12:e063263. doi: 10.1136/bmjopen-2022-063263

PubMed Abstract | Crossref Full Text | Google Scholar

183. Swoboda, KJ, and Nery, FC. Harnessing the power of the patient perspective for rare disease therapeutics. Neurology. (2018) 91:585–6. doi: 10.1212/WNL.0000000000006230

PubMed Abstract | Crossref Full Text | Google Scholar

184. Togo, CCG, Zidorio, APC, Gonçalves, VSS, Hubbard, L, de Carvalho, KMB, and Dutra, ES. Quality of life in people with epidermolysis bullosa: a systematic review. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. (2020) 29:1731–45. doi: 10.1007/s11136-020-02495-5

PubMed Abstract | Crossref Full Text | Google Scholar

185. Reimer, A, Bruckner-Tuderman, L, and Ott, H. Mapping health care of rare diseases: the example of epidermolysis bullosa in Germany. Orphanet J Rare Dis. (2018) 13:197. doi: 10.1186/s13023-018-0944-x

PubMed Abstract | Crossref Full Text | Google Scholar

186. Ryder, S, Leadley, RM, Armstrong, N, Westwood, M, de Kock, S, Butt, T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. (2017) 12:79. doi: 10.1186/s13023-017-0631-3

PubMed Abstract | Crossref Full Text | Google Scholar

187. Rozensztrauch, A, and Śmigiel, R. Quality of life in children with Prader–Willi syndrome and the impact of the disease on the functioning of families. Int J Environ Res Public Health. (2022) 19:16330. doi: 10.3390/ijerph192316330

PubMed Abstract | Crossref Full Text | Google Scholar

188. Belzer, LT, Wright, SM, Goodwin, EJ, Singh, MN, and Carter, BS. Psychosocial considerations for the child with rare disease: a review with recommendations and calls to action. Children. (2022) 9:933. doi: 10.3390/children9070933

PubMed Abstract | Crossref Full Text | Google Scholar

189. Adams, D, Clarke, S, Griffith, G, Howlin, P, Moss, J, Petty, J, et al. Mental health and well-being in mothers of children with rare genetic syndromes showing chronic challenging behavior: a Cross-sectional and longitudinal study. Am J Intellect Dev Disabil. (2018) 123:241–53. doi: 10.1352/1944-7558-123.3.241

PubMed Abstract | Crossref Full Text | Google Scholar

190. Quittner, AL, Goldbeck, L, Abbott, J, Duff, A, Lambrecht, P, Solé, A, et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of the international depression epidemiological study across nine countries. Thorax. (2014) 69:1090–7. doi: 10.1136/thoraxjnl-2014-205983

PubMed Abstract | Crossref Full Text | Google Scholar

191. Maltseva, M, Schubert-Bast, S, Zöllner, JP, Bast, T, Mayer, T, Von Spiczak, S, et al. Sleep quality, anxiety, symptoms of depression, and caregiver burden among those caring for patients with Dravet syndrome: a prospective multicenter study in Germany. Orphanet J Rare Dis. (2023) 18:98. doi: 10.1186/s13023-023-02697-3

PubMed Abstract | Crossref Full Text | Google Scholar

192. Domaradzki, J, and Walkowiak, D. Caring for children with Dravet syndrome: exploring the daily challenges of family caregivers. Children. (2023) 10:1410. doi: 10.3390/children10081410

PubMed Abstract | Crossref Full Text | Google Scholar

193. Boettcher, J, Denecke, J, Barkmann, C, and Wiegand-Grefe, S. Quality of life and mental health in mothers and fathers caring for children and adolescents with rare diseases requiring long-term mechanical ventilation. Int J Environ Res Public Health. (2020) 17:8975. doi: 10.3390/ijerph17238975

PubMed Abstract | Crossref Full Text | Google Scholar

194. Rezaei, F, Sanagoo, A, Peyrovi, H, and Jouybari, L. Persistent suffering: living experiences of patients with rare disease: an interpretative phenomenological study. J Educ Health Promot. (2023) 12:224. doi: 10.4103/jehp.jehp_1010_22

PubMed Abstract | Crossref Full Text | Google Scholar

195. Danese, E, and Lippi, G. Rare diseases: the paradox of an emerging challenge. Ann Transl Med. (2018) 6:329. doi: 10.21037/atm.2018.09.04

PubMed Abstract | Crossref Full Text | Google Scholar

196. Verger, S, Negre, F, Fernández-Hawrylak, M, and Paz-Lourido, B. The impact of the coordination between healthcare and educational personnel on the health and inclusion of children and adolescents with rare diseases. Int J Environ Res Public Health. (2021) 18:6538. doi: 10.3390/ijerph18126538

PubMed Abstract | Crossref Full Text | Google Scholar

197. García-Perales, R, Palomares-Ruiz, A, Ordóñez-García, L, and García-Toledano, E. Rare diseases in the educational field: knowledge and perceptions of Spanish teachers. Int J Environ Res Public Health. (2022) 19:6057. doi: 10.3390/ijerph19106057

PubMed Abstract | Crossref Full Text | Google Scholar

198. Branch-Smith, C, Shaw, T, Lin, A, Runions, K, Payne, D, Nguyen, R, et al. Bullying and mental health amongst Australian children and young people with cystic fibrosis. Am J Orthopsychiatry. (2018) 88:402–12. doi: 10.1037/ort0000289

PubMed Abstract | Crossref Full Text | Google Scholar

199. Röjvik, A, Jaeger, G, Hjelmquist, E, and Falkman, KW. Creating optimal educational settings for children with rare diseases – a working method. Eur J Spec Needs Educ. (2024) 39:759–73. doi: 10.1080/08856257.2023.2294237

Crossref Full Text | Google Scholar

200. Omosigho, PO, John, OO, Musa, MB, Aboelhassan, YMEI, Olabode, ON, Bouaddi, O, et al. Stigma and infectious diseases in Africa: examining impact and strategies for reduction. Ann Med Surg. (2023) 85:6078–82. doi: 10.1097/MS9.0000000000001470

PubMed Abstract | Crossref Full Text | Google Scholar

201. Depping, MK, Uhlenbusch, N, von Kodolitsch, Y, Klose, HFE, Mautner, VF, and Löwe, B. Supportive care needs of patients with rare chronic diseases: multi-method, cross-sectional study. Orphanet J Rare Dis. (2021) 16:44. doi: 10.1186/s13023-020-01660-w

PubMed Abstract | Crossref Full Text | Google Scholar

202. Gómez-Díaz, B, Zamora-González, EO, Miranda-Duarte, A, Roque-Ramírez, B, Vázquez-Cárdenas, NA, Martínez-Gómez, G, et al. Assessing knowledge, perceptions, awareness and attitudes on rare diseases among health care providers and health students in Mexico. Rare. (2023) 1:100005. doi: 10.1016/j.rare.2023.100005

PubMed Abstract | Crossref Full Text | Google Scholar

203. Lyon, ME, and Wiener, L. Special issue: psychosocial considerations for children and adolescents living with a rare disease. Children. (2022) 9:1099. doi: 10.3390/children9071099

PubMed Abstract | Crossref Full Text | Google Scholar

204. Domaradzki, J, and Walkowiak, D. Ultra-rare ultra-care: assessing the impact of caring for children with ultra rare diseases. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. (2024) 48:78–84. doi: 10.1016/j.ejpn.2023.12.003

PubMed Abstract | Crossref Full Text | Google Scholar

205. Spurr, S, Danford, CA, Roberts, KJ, Sheppard-LeMoine, D, Machado Silva-Rodrigues, F, Darezzo Rodrigues Nunes, M, et al. Fathers’ experiences of caring for a child with a chronic illness: a systematic review. Child Basel Switz. (2023) 10:197. doi: 10.3390/children10020197

PubMed Abstract | Crossref Full Text | Google Scholar

206. Daly, C, Ruane, P, O’Reilly, K, Longworth, L, and Vega-Hernandez, G. Caregiver burden in cystic fibrosis: a systematic literature review. Ther Adv Respir Dis. (2022) 16:17534666221086416. doi: 10.1177/17534666221086416

PubMed Abstract | Crossref Full Text | Google Scholar

207. Soelaeman, RH, Smith, MG, Sahay, K, Tilford, JM, Goodenough, D, Paramsothy, P, et al. Labor market participation and productivity costs for female caregivers of minor male children with Duchenne and Becker muscular dystrophies. Muscle Nerve. (2021) 64:717–25. doi: 10.1002/mus.27429

PubMed Abstract | Crossref Full Text | Google Scholar

208. Khosla, N, and Valdez, R. A compilation of national plans, policies and government actions for rare diseases in 23 countries. Intractable Rare Dis Res. (2018) 7:213–22. doi: 10.5582/irdr.2018.01085

PubMed Abstract | Crossref Full Text | Google Scholar

209. Lopes-Júnior, LC, Ferraz, VEF, Lima, RAG, Schuab, SIPC, Pessanha, RM, Luz, GS, et al. Health policies for rare disease patients: a scoping review. Int J Environ Res Public Health. (2022) 19:15174. doi: 10.3390/ijerph192215174

PubMed Abstract | Crossref Full Text | Google Scholar

210. United Nations General Assembly. (2021). Available online at: https://documents.un.org/doc/undoc/gen/n23/420/62/pdf/n2342062.pdf (Accessed January 15, 2025).

Google Scholar

211. O’Mahony, B, Dolan, G, Nugent, D, and Goodman, C. The international Haemophilia access strategy council. Patient Centred Value Framework Haemophilia Haemophilia. (2018) 24:873–9. doi: 10.1111/hae.13456

Crossref Full Text | Google Scholar

212. Choudhury, MC, and Saberwal, G. The role of patient organizations in the rare disease ecosystem in India: an interview based study. Orphanet J Rare Dis. (2019) 14:117. doi: 10.1186/s13023-019-1093-6

PubMed Abstract | Crossref Full Text | Google Scholar

213. CCY, C, Hong Kong Genome ProjectATW, C, and BHY, C. Rare disease emerging as a global public health priority. Front. Public Health. (2022) 10:1028545. doi: 10.3389/fpubh.2022.1028545

PubMed Abstract | Crossref Full Text | Google Scholar

214. Mikami, K. Orphans in the market: the history of orphan drug policy. Soc Hist Med. (2019) 32:609–30. doi: 10.1093/shm/hkx098

PubMed Abstract | Crossref Full Text | Google Scholar

215. Montserrat, A, and Taruscio, D. Policies and actions to tackle rare diseases at European level. Ann Ist Super Sanita. (2019) 55:296–304. doi: 10.4415/ANN_19_03_17

PubMed Abstract | Crossref Full Text | Google Scholar

216. Wainstock, D, and Katz, A. Advancing rare disease policy in Latin America: a call to action. Lancet Reg Health Am. (2023) 18:100434. doi: 10.1016/j.lana.2023.100434

PubMed Abstract | Crossref Full Text | Google Scholar

217. European Reference Networks - European Commission. (2024). Available online at: https://health.ec.europa.eu/rare-diseases-and-european-reference-networks/european-reference-networks_en (Accessed January 15, 2025).

Google Scholar

218. Boulanger, V, Schlemmer, M, Rossov, S, Seebald, A, and Gavin, P. Establishing patient registries for rare diseases: rationale and challenges. Pharm Med. (2020) 34:185–90. doi: 10.1007/s40290-020-00332-1

PubMed Abstract | Crossref Full Text | Google Scholar

219. Mishra, S, Bhat, D, and Venkatesh, MP. Navigating health policies and programs in India: exploring opportunities to improve rare disease management and orphan drug research. Orphanet J Rare Dis. (2024) 19:446. doi: 10.1186/s13023-024-03377-6

PubMed Abstract | Crossref Full Text | Google Scholar

220. Grand, TS, Ren, S, Hall, J, Åström, DO, Regnier, S, and Thokala, P. Issues, challenges and opportunities for economic evaluations of orphan drugs in rare diseases: an umbrella review. PharmacoEconomics. (2024) 42:619–31. doi: 10.1007/s40273-024-01370-2

PubMed Abstract | Crossref Full Text | Google Scholar

221. Witt, S, Schuett, K, Wiegand-Grefe, S, Boettcher, J, and Quitmann, J. Living with a rare disease - experiences and needs in pediatric patients and their parents. Orphanet J Rare Dis. (2023) 18:242. doi: 10.1186/s13023-023-02837-9

PubMed Abstract | Crossref Full Text | Google Scholar

222. Auvin, S, Irwin, J, Abi-Aad, P, and Battersby, A. The problem of rarity: estimation of prevalence in rare disease. Value Health. (2018) 21:501–7. doi: 10.1016/j.jval.2018.03.002

PubMed Abstract | Crossref Full Text | Google Scholar

223. Julkowska, D, Austin, CP, Cutillo, CM, Gancberg, D, Hager, C, Halftermeyer, J, et al. The importance of international collaboration for rare diseases research: a European perspective. Gene Ther. (2017) 24:562–71. doi: 10.1038/gt.2017.29

PubMed Abstract | Crossref Full Text | Google Scholar

224. García-Pérez, L, Linertová, R, Valcárcel-Nazco, C, Posada, M, Gorostiza, I, and Serrano-Aguilar, P. Cost-of-illness studies in rare diseases: a scoping review. Orphanet J Rare Dis. (2021) 16:178. doi: 10.1186/s13023-021-01815-3

PubMed Abstract | Crossref Full Text | Google Scholar

225. Ngoumou, RD, and Feudjio, YBD. The management of rare disease patients from a grassroot perspective: the role of patients’ organizations in the global recognition of rare diseases in Cameroon. Pan Afr Med J. (2024) 47:64. doi: 10.11604/pamj.2024.47.64.38226

PubMed Abstract | Crossref Full Text | Google Scholar

226. Edu, E, Okesanya, OJ, and Lucero-Prisno, DE. Burden of rare diseases in Africa: recommendations for improving access to medications and healthcare. J Med Surg Public Health. (2024) 2:100032. doi: 10.1016/j.glmedi.2023.100032

PubMed Abstract | Crossref Full Text | Google Scholar

227. Baynam, G, Julkowska, D, Bowdin, S, Hermes, A, McMaster, CR, Prichep, E, et al. Advancing diagnosis and research for rare genetic diseases in indigenous peoples. Nat Genet. (2024) 56:189–93. doi: 10.1038/s41588-023-01642-1

PubMed Abstract | Crossref Full Text | Google Scholar

228. Mudau, MM, Seymour, H, Nevondwe, P, Kerr, R, Spencer, C, Feben, C, et al. A feasible molecular diagnostic strategy for rare genetic disorders within resource-constrained environments. J Community Genet. (2024) 15:39–48. doi: 10.1007/s12687-023-00674-8

PubMed Abstract | Crossref Full Text | Google Scholar

229. Schneider, NB, Roos, EC, Staub, ALP, Bevilacqua, IP, de Almeida, AC, de Camargo, MT, et al. Estimated costs for Duchenne muscular dystrophy care in Brazil. Orphanet J Rare Dis. (2023) 18:159. doi: 10.1186/s13023-023-02767-6

PubMed Abstract | Crossref Full Text | Google Scholar

230. Lumaka, A, Carstens, N, Devriendt, K, Krause, A, Kulohoma, B, Kumuthini, J, et al. Increasing African genomic data generation and sharing to resolve rare and undiagnosed diseases in Africa: a call-to-action by the H3Africa rare diseases working group. Orphanet J Rare Dis. (2022) 17:230. doi: 10.1186/s13023-022-02391-w

PubMed Abstract | Crossref Full Text | Google Scholar

231. Shah, KK, Kogut, S, and Slitt, A. Challenges in evaluating safety and efficacy in drug development for rare diseases: a review for pharmacists. J Pharm Pract. (2021) 34:472–9. doi: 10.1177/0897190020930972

PubMed Abstract | Crossref Full Text | Google Scholar

232. Economist Impact. Perspectives. One stripe at a time: raising awareness of rare diseases in Latin America. Available online at: https://impact.economist.com/perspectives/health/one-stripe-time-raising-awareness-rare-diseases-latin-america (Accessed January 15, 2025).

Google Scholar

233. Simpson, A, Bloom, L, Fulop, NJ, Hudson, E, Leeson-Beevers, K, Morris, S, et al. How are patients with rare diseases and their carers in the UK impacted by the way care is coordinated? An exploratory qualitative interview study. Orphanet J Rare Dis. (2021) 16:76. doi: 10.1186/s13023-020-01664-6

PubMed Abstract | Crossref Full Text | Google Scholar

234. Li, X, Liu, M, Lin, J, Li, B, Zhang, X, Zhang, S, et al. A questionnaire-based study to comprehensively assess the status quo of rare disease patients and care-givers in China. Orphanet J Rare Dis. (2021) 16:327. doi: 10.1186/s13023-021-01954-7

PubMed Abstract | Crossref Full Text | Google Scholar

235. Domaradzki, J, and Walkowiak, D. Evaluating the challenges and needs of parents caring for children with Williams syndrome: a preliminary study from Poland. Res Dev Disabil. (2024) 145:104669. doi: 10.1016/j.ridd.2024.104669

PubMed Abstract | Crossref Full Text | Google Scholar

236. Teutsch, S, Zurynski, Y, Eslick, GD, Deverell, M, Christodoulou, J, Leonard, H, et al. Australian children living with rare diseases: health service use and barriers to accessing care. World J Pediatr WJP. (2023) 19:701–9. doi: 10.1007/s12519-022-00675-6

PubMed Abstract | Crossref Full Text | Google Scholar

237. Velvin, G, Johnsen, V, Lidal, IB, and Berg, E. Parental intervention program for preschool children with rare diseases - a mixed methods evaluation of parents’ experiences and utility. Orphanet J Rare Dis. (2023) 18:327. doi: 10.1186/s13023-023-02935-8

PubMed Abstract | Crossref Full Text | Google Scholar

238. Meregaglia, M, Nicod, E, and Drummond, M. The estimation of health state utility values in rare diseases: overview of existing techniques. Int J Technol Assess Health Care. (2020) 36:469–73. doi: 10.1017/S0266462320000665

PubMed Abstract | Crossref Full Text | Google Scholar

239. Korth-Bradley, JM. Regulatory framework for drug development in rare diseases. J Clin Pharmacol. (2022) 62:S15–26. doi: 10.1002/jcph.2171

PubMed Abstract | Crossref Full Text | Google Scholar

240. SYa, V, Nikolaeva, EA, Sokolov, AA, Kopishinskaia, SV, Gamirova, RG, and Khalmatova, BT. Children with rare diseases: ethical, social, psychological and medical issues. Ross Vestn Perinatol Pediatr Russ Bull Perinatol Pediatr. (2019) 64:149–54. doi: 10.21508/1027-4065-2019-64-5-149-154

Crossref Full Text | Google Scholar

241. Abdallah, K, Claes, K, Huys, I, Follon, L, Calis, C, and Simoens, S. Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study. Orphanet J Rare Dis. (2022) 17:429. doi: 10.1186/s13023-022-02571-8

PubMed Abstract | Crossref Full Text | Google Scholar

242. About the DDRMD. (2025). Available online at: https://www.ddrmd.nl/ (Accessed January 15, 2025).

Google Scholar

243. Jonker, CJ, de Vries, ST, van den Berg, HM, McGettigan, P, Hoes, AW, and Mol, PGM. Capturing data in rare disease registries to support regulatory decision making: a survey study among industry and other stakeholders. Drug Saf. (2021) 44:853–61. doi: 10.1007/s40264-021-01081-z

PubMed Abstract | Crossref Full Text | Google Scholar

244. Simoens, S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. (2011) 6:42. doi: 10.1186/1750-1172-6-42

PubMed Abstract | Crossref Full Text | Google Scholar

245. Scherman, D, and Fétro, C. Drug repositioning for rare diseases: knowledge-based success stories. Therapie. (2020) 75:161–7. doi: 10.1016/j.therap.2020.02.007

PubMed Abstract | Crossref Full Text | Google Scholar

246. Alonso Ruiz, A, Large, K, Moon, S, and Vieira, M. Pharmaceutical policy and innovation for rare diseases: a narrative review. F1000Research. (2023) 12:211. doi: 10.12688/f1000research.130809.2

PubMed Abstract | Crossref Full Text | Google Scholar

247. Seifert, O. HealthLumen. (2024). Available online at: https://www.healthlumen.com/supporting-rare-disease-patient-advocacy-with-epidemiological-insights/ (Accessed January 15, 2025).

Google Scholar

248. Global Partnerships. National organization for rare disorders. (2022). Available online at: https://rarediseases.org/community-support/global-partnerships/ (Accessed January 14, 2025).

Google Scholar

249. Héon-Klin, V. European reference networks for rare diseases: what is the conceptual framework? Orphanet J Rare Dis. (2017) 12:137. doi: 10.1186/s13023-017-0676-3

PubMed Abstract | Crossref Full Text | Google Scholar

250. Hedley, V, Bolz-Johnson, M, Hernando, I, Kenward, R, Nabbout, R, Romero, C, et al. Together4RD position statement on collaboration between European reference networks and industry. Orphanet J Rare Dis. (2023) 18:272. doi: 10.1186/s13023-023-02853-9

PubMed Abstract | Crossref Full Text | Google Scholar

251. dos Santos, VB, Bernabé, CH, Zhang, S, Abaza, H, Benis, N, Cámara, A, et al. Towards FAIRification of sensitive and fragmented rare disease patient data: challenges and solutions in European reference network registries. Orphanet J Rare Dis. (2022) 17:436. doi: 10.1186/s13023-022-02558-5

PubMed Abstract | Crossref Full Text | Google Scholar